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Measles, Mumps, and Rubella—
Vaccine Use and Strategies for Elimination of
Measles, Rubella, and Congenital Rubella Syndrome
and Control of Mumps:
Recommendations of the Advisory Committee on
Immunization Practices (ACIP)
SUMMARY
These revised recommendations of the Advisory Committee on Immuniza-
tion Practices (ACIP) on measles, mumps, and rubella prevention supersede
recommendations published in 1989 and 1990. This statement summarizes
the goals and current strategies for measles, rubella, and congenital rubella syn-
drome (CRS) elimination and for mumps reduction in the United States.
Changes from previous recommendations include 
• Emphasis on the use of combined MMR vaccine for most indications;
• A change in the recommended age for routine vaccination to 12–15 months for
the first dose of MMR, and to 4–6 years for the second dose of MMR;
• A recommendation that all states take immediate steps to implement a two dose
MMR requirement for school entry and any additional measures needed to en-
sure that all school-aged children are vaccinated with two doses of MMR by 2001;
• A clarification of the role of serologic screening to determine immunity;
• A change in the criteria for determining acceptable evidence of rubella immunity;
• A recommendation that all persons who work in health-care facilities have ac-
ceptable evidence of measles and rubella immunity;
• Changes in the recommended interval between administration of immune globu-
lin and measles vaccination; and
• Updated information on adverse events and contraindications, particularly for
persons with severe HIV infection, persons with a history of egg allergy or gelatin
allergy, persons with a history of thrombocytopenia, and persons receiving ster-
oid therapy.
INTRODUCTION
Since monovalent vaccines containing measles, rubella, and mumps vaccine
viruses—and subsequently combined measles-mumps-rubella (MMR) vaccine—were
licensed, the numbers of reported cases of measles, mumps, rubella, and congenital
rubella syndrome (CRS) have decreased by more than 99%. In 1993, the Childhood
Immunization Initiative established goals of eliminating indigenous transmission
of measles and rubella in the United States by 1996. Subsequently, the goals of the
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initiative were extended to include reducing the number of reported mumps cases to
≤1600 by 1996. U.S. Public Health Service year 2000 objectives include eliminating
measles, rubella, and congenital rubella syndrome, and reducing mumps incidence to
<500 reported cases per year. Since 1995, fewer cases of measles, rubella, and mumps
have been reported than at any time since nationwide disease reporting began, and
elimination of indigenous transmission appears feasible. These recommendations are
intended to hasten the achievement of these disease elimination goals.
Measles
Clinical Characteristics
The incubation period of measles (rubeola) averages 10–12 days from exposure
to prodrome and 14 days from exposure to rash (range: 7–18 days). The disease can
be severe and is most frequently complicated by diarrhea, middle ear infection, or
bronchopneumonia. Encephalitis occurs in approximately one of every 1,000 reported
cases; survivors of this complication often have permanent brain damage and mental
retardation. Death occurs in 1–2 of every 1,000 reported measles cases in the United
States. The risk for death from measles or its complications is greater for infants,
young children, and adults than for older children and adolescents. The most common
causes of death are pneumonia and acute encephalitis. In developing countries, mea-
sles is often more severe and the case-fatality rate can be as high as 25%.
Subacute sclerosing panencephalitis (SSPE) is a rare degenerative disease of the
central nervous system associated with measles virus. Signs and symptoms of the
disease appear years after measles infection. Widespread use of measles vaccine has
essentially eliminated SSPE from the United States (1 ).
Measles illness during pregnancy leads to increased rates of premature labor,
spontaneous abortion, and low birth weight among affected infants (2–5 ). Birth de-
fects, with no definable pattern of malformation, have been reported among infants
born to women infected with measles during pregnancy, but measles infection has not
been confirmed as the cause of the malformations.
Measles can be severe and prolonged among immunocompromised persons, par-
ticularly those who have certain leukemias, lymphomas, or human immunodeficiency
virus (HIV) infection. Among these persons, measles may occur without the typical
rash and a patient may shed measles virus for several weeks after the acute illness
(6,7 ).
Measles Elimination
Before measles vaccine was licensed in 1963, an average of 400,000 measles cases
were reported each year in the United States (8 ). However, because virtually all chil-
dren acquired measles, the number of cases probably approached 3.5 million per year
(i.e., an entire birth cohort).
Since measles vaccine became available, professional and voluntary medical and
public health organizations have collaborated in vaccination programs that have re-
duced the reported incidence of measles by >99%. During the late 1960s and early
1970s, the number of reported cases decreased to approximately 22,000–75,000 cases
per year. Although measles incidence decreased substantially in all age groups, the
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greatest decrease occurred among children aged <10 years. A less marked decrease
also occurred among older children.
During 1978, the Department of Health, Education, and Welfare (DHEW) initiated a
Measles Elimination Program with the goal of eliminating indigenous measles from
the United States by October 1, 1982. The three components of this program were
a) maintenance of high levels of immunity with a single dose of measles vaccine,
b) enhanced surveillance of disease, and c) aggressive outbreak control. As a result of
this program, the number of cases reported annually decreased from 26,871 during
1978 to 1,497 during 1983. However, an average of 3,750 cases was reported each year
during 1984–1988; 58% of these cases occurred among children aged ≥10 years,
most of whom had received only one dose of measles vaccine (9 ). Recurrent measles
outbreaks among vaccinated school-aged children prompted both the Advisory Com-
mittee on Immunization Practices (ACIP) and the American Academy of Pediatrics
(AAP) in 1989 to recommend that all children receive two doses of measles-containing
vaccine, preferably as MMR. Although administration of the second dose was origi-
nally recommended either at entry to primary school (ACIP) or middle/ secondary
school (AAP), ACIP, the AAP, and the American Academy of Family Physicians (AAFP)
now recommend that a child receive the second dose before school entry, rather than
delaying it until the child is aged 11–12 years.
During 1989–1991, a major resurgence of measles occurred in the United States.
More than 55,000 cases and >120 measles-related deaths were reported. The resur-
gence was characterized by an increasing proportion of cases among unvaccinated
preschool-aged children, particularly those resident in urban areas (10–12 ).
Multiple barriers to timely vaccination of preschool-aged children were identified
during investigation of the 1989–1991 measles resurgence. Efforts to increase vaccina-
tion coverage among preschool-aged children emphasized vaccination as close to
the recommended age as possible. These efforts, coupled with ongoing implementa-
tion of the two-dose MMR recommendation, reduced reported measles cases from
2,237 in 1992 to 312 in 1993 (9 ). Although 963 measles cases were reported in 1994,
measles incidence again declined in 1995, when 309 cases were reported (13 ). In
1996, 508 cases were reported, of which 65 were classified as international importa-
tions (14 ).
In 1993, the Childhood Immunization Initiative called for the elimination from the
United States by 1996 of indigenous transmission of six childhood diseases, including
rubella, congenital rubella syndrome (CRS), and measles (10 ). In September 1994, the
Pan American Health Organization (PAHO) adopted a similar goal of eliminating mea-
sles throughout the Americas by 2000 (15 ). Both epidemiologic and laboratory
evidence suggest that the transmission of indigenous measles was interrupted in the
United States for the first time during 1993 (16,17 ).
However, even after indigenous measles transmission has been eliminated, mea-
sles cases caused by the importation of the virus from other countries will continue
to occur. Sustaining measles elimination will require continuing efforts. Enhanced
surveillance for measles must be maintained and disease control activities must be
undertaken immediately when suspected cases of measles are reported. The major
challenges to sustaining the elimination of measles from the United States are a) con-
tinuing to vaccinate all children aged 12–15 months with a first dose of MMR,
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b) ensuring that all school-aged children receive a second dose of MMR vaccine, and
c) working with other countries to set and achieve national measles elimination goals.
Rubella And Congenital Rubella Syndrome (CRS)
Clinical Characteristics
Rubella is an exanthematous illness characterized by nonspecific signs and symp-
toms including transient erythematous and sometimes pruritic rash, postauricular or
suboccipital lymphadenopathy, arthralgia, and low-grade fever. Clinically similar ex-
anthematous illnesses are caused by parvovirus, adenoviruses, and enteroviruses.
Moreover, 25%–50% of rubella infections are subclinical. The incubation period ranges
from 12 to 23 days. Before rubella vaccine was available, the disease was common
among children and young adults.
Among adults infected with rubella, transient polyarthralgia or polyarthritis occur
frequently. These manifestations are particularly common among women (18 ). Cen-
tral nervous system complications (i.e., encephalitis) occur at a ratio of 1 per 6,000
cases and are more likely to affect adults. Thrombocytopenia occurs at a ratio of 1 per
3,000 cases and is more likely to affect children.
The most important consequences of rubella are the miscarriages, stillbirths, fetal
anomalies, and therapeutic abortions that result when rubella infection occurs during
early pregnancy, especially during the first trimester. An estimated 20,000 cases of
CRS occurred during 1964–1965 during the last U.S. rubella epidemic before rubella
vaccine became available.
The anomalies most commonly associated with CRS are auditory (e.g., sensorineu-
ral deafness), ophthalmic (e.g., cataracts, microphthalmia, glaucoma, chorioretinitis),
cardiac (e.g., patent ductus arteriosus, peripheral pulmonary artery stenosis, atrial or
ventricular septal defects), and neurologic (e.g., microcephaly, meningoencephalitis,
mental retardation). In addition, infants with CRS frequently exhibit both intrauterine
and postnatal growth retardation. Other conditions sometimes observed among pa-
tients who have CRS include radiolucent bone defects, hepatosplenomegaly,
thrombocytopenia, and purpuric skin lesions.
Infants who are moderately or severely affected by CRS are readily recognizable at
birth, but mild CRS (e.g., slight cardiac involvement or deafness) may be detected
months or years after birth, or not at all. Although CRS has been estimated to occur
among 20%–25% of infants born to women who acquire rubella during the first
20 weeks of pregnancy, this figure may underestimate the risk for fetal infection and
birth defects. When infants born to mothers who were infected during the first
8 weeks of gestation were followed for 4 years, 85% were found to be affected (19 ).
The risk for any defect decreases to approximately 52% for infections that occur dur-
ing the ninth to twelfth weeks of gestation. Infection after the twentieth week of
gestation rarely causes defects. Inapparent (subclinical) maternal rubella infection can
also cause congenital malformations. Fetal infection without clinical signs of CRS can
occur during any stage of pregnancy.
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Rubella Elimination
Before rubella vaccine was licensed during 1969, rubella incidence was greatest
among preschool and elementary school children. Therefore, vaccination cam-
paigns initially targeted children in kindergarten and the early grades of elementary
school, with the aim of interrupting circulation of the virus and eliminating the risk for
exposure among susceptible pregnant women. The risks associated with administer-
ing a potentially teratogenic live virus vaccine to young women of childbearing age
were not known. During 1969–1976, reported rubella cases decreased from 57,600 to
12,400. However, during 1975–1977, 62% of reported rubella cases occurred among
persons aged >15 years compared with 23% of cases occurring during 1966–1968,
and serologic studies suggested that 10%–15% of adults remained susceptible to ru-
bella (20 ).
The number of CRS cases reported nationwide decreased by 69% from 69 in 1970
to 22 in 1976. Rubella outbreaks continued to occur among older adolescents and
young adults (e.g, in military camps, high schools, colleges, and universities). In 1977,
ACIP modified its recommendations to include the vaccination of susceptible postpu-
bertal girls and women. During the same year, the DHEW undertook the National
Childhood Immunization Initiative, which sought to immunize >90% of the nation’s
children against all vaccine-preventable diseases. Enforcement of requirements for
vaccination before school entry was part of the initiative. The number of reported ru-
bella and CRS cases decreased after these programs were implemented, from 20,395
rubella cases and 29 CRS cases in 1977 to 752 rubella cases and 2 CRS cases in 1984.
In 1988, 225 cases of rubella were reported in the United States, the fewest since na-
tional reporting began.
However, because of outbreaks among unvaccinated adults (e.g., in prisons, col-
leges, and workplaces), >1000 rubella cases were reported in 1990 and again in 1991.
The largest outbreak and the greatest number of CRS cases occurred among children
and adults in religious communities that do not accept vaccination. Since 1992, re-
ported indigenous rubella and CRS have continued to occur at a low but relatively
constant endemic level with an annual average of <200 rubella cases (128 cases in
1995 and 213 cases in 1996). Four confirmed CRS cases occurred in 1995 and 2 in 1996.
However, in the United States, surveillance for CRS relies on a passive system. Conse-
quently, the reported annual totals of CRS are regarded as minimum figures, rep-
resenting an estimated 40%–70% of all cases (21,22 ).
During 1992–1997, 65% of reported cases of rubella occurred among persons aged
≥20 years. In addition, recent evidence suggests that the risk for both rubella and CRS
is increased among persons of Hispanic ethnicity, particularly those born outside the
United States. Outbreaks of rubella in California (1990–1991), Massachusetts (1993–
1994), Connecticut (1995), and North Carolina (1996 and 1997) have occurred primarily
among persons of Hispanic origin. During 1985–1995, the ethnicity of a total of 89 chil-
dren with laboratory-confirmed or clinically compatible cases of CRS was known;
35 (39%) were of Hispanic origin (23–27 ).
Recent data indicate that the rate of rubella susceptibility and risk for rubella infec-
tion are highest among young adults. During 1992–94, approximately 8% of persons
aged 15–29 years were estimated to lack serologic evidence of immunity to rubella
(CDC, unpublished data). Data from two recent studies indicate that vaccine-induced
rubella antibody levels among adolescents may have decreased during the 9–14 years
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that had elapsed since they were initially vaccinated. However, recent rubella surveil-
lance data do not indicate that rubella and CRS are increasing among vaccinated
persons (28 ) (CDC, unpublished data).
The primary objective of the rubella immunization program is the prevention of
CRS. The major components of the rubella and CRS elimination strategy are achieving
and maintaining high immunization levels for children and adults, especially women
of childbearing age; conducting accurate surveillance for rubella and CRS; and under-
taking control measures promptly when a rubella outbreak occurs. Since the late




Persons in whom “classical” mumps develops have bilateral or (less commonly)
unilateral parotitis, with onset an average of 16–18 days after exposure. Parotitis may
be preceded by fever, headache, malaise, myalgia, and anorexia. Only 30%–40% of
mumps infections produce typical acute parotitis; 15%–20% of infections are asymp-
tomatic and up to 50% of infections are associated with nonspecific or primarily
respiratory symptoms (29,30 ). Inapparent infection may be more common among
adults than children; parotitis occurs more commonly among children aged 2–9 years
(30,31 ). Serious complications of mumps infection can occur without evidence of
parotitis (29,32,33 ).
Most serious complications of mumps are more common among adults than
among children (29,34 ). Although orchitis may occur among up to 38% of postpuber-
tal men in whom mumps develops, sterility is thought to occur only rarely (35 ).
Aseptic meningitis affects 4%–6% of persons with clinical cases of mumps and typi-
cally is mild (29,36–38 ). However, mumps meningoencephalitis can cause permanent
sequelae, including paralysis, seizures, cranial nerve palsies, aqueductal stenosis, and
hydrocephalus (39–41 ). In the prevaccine era, mumps was a major cause of sensor-
ineural deafness among children. Deafness may be sudden in onset, bilateral, and
permanent (42–44 ).
Among women in whom mumps develops during the first trimester of pregnancy,
an increased risk for fetal death has been observed (45 ). However, mumps infection
during pregnancy is not associated with congenital malformations (46 ).
Mumps Control
In the United States, the reported incidence of mumps decreased steadily after the
introduction of live mumps vaccine in 1967 and the recommendation for its routine
use in 1977. In 1995, 906 cases were reported, representing a 99% decrease from the
185,691 cases reported in 1968. The enactment and enforcement of state vaccination
laws requiring that students be vaccinated before school entry has contributed more
to reducing mumps incidence than any other measure (47 ). During the 1980s and
early 1990s, mumps incidence was lowest in states where comprehensive vaccination
laws were enforced. States where vaccination laws were less comprehensive reported
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intermediate mumps incidence, and the highest incidence was reported in states did
not have such laws (47–51).
Mumps incidence is now very low in all areas of the United States. The substantial
reduction in mumps incidence during the past few years may reflect the change in the
recommendations for use of MMR vaccine. The implementation of the two-dose MMR
vaccination schedule likely decreased mumps incidence further by immunizing chil-
dren among whom the first dose of mumps antigen did not elicit an immune response
(52,53 ). The principal strategy to prevent mumps is to achieve and maintain high im-
munization levels by routinely vaccinating all children with two doses of MMR.
VACCINE PREPARATIONS
Measles, rubella, and mumps vaccines are available in monovalent measles (At-
tenuvax®, Merck & Co., Inc. ), rubella (Meruvax®, Merck & Co., Inc. ), or mumps
(Mumpsvax®, Merck & Co., Inc. ) form and in combinations: measles-mumps-rubella
(MMR) (M-M-R II®, Merck & Co., Inc. ), measles-rubella (MR) (M-R-Vax®, Merck & Co.,
Inc. ), and rubella-mumps (Biavax II®, Merck & Co., Inc. ) vaccines. Each dose of the
combined or monovalent vaccines contains approximately 0.3 milligrams of human
albumin, 25 micrograms of neomycin, 14.5 milligrams of sorbitol, and 14.5 milligrams
of hydrolyzed gelatin (Merck & Co., Inc., manufacturer’s package insert ). Live measles
vaccine and live mumps vaccine are produced in chick embryo cell culture. Live ru-
bella vaccine is grown in human diploid cell culture.
Measles Component
Since 1963, when both inactivated and live attenuated (Edmonston B strain) vac-
cines were licensed, the type of measles vaccine used in the United States has
changed several times. Distribution of the inactivated and live Edmonston B vaccines
ceased after 1967 and 1975, respectively. Distribution in the United States of a live,
further attenuated vaccine (Schwarz strain) first introduced in 1965 has also ceased. A
live, further attenuated preparation of the Enders-Edmonston virus strain that is
grown in chick embryo fibroblast cell culture, licensed in 1968, is the only measles
virus vaccine now available in the United States. This further attenuated vaccine (for-
merly called “Moraten”) causes fewer adverse reactions than the Edmonston B
vaccine.
Measles vaccine produces an inapparent or mild, noncommunicable infection.
Measles antibodies develop among approximately 95% of children vaccinated at
age 12 months and 98% of children vaccinated at age 15 months (CDC, unpublished
data). Studies indicate that, if the first dose is administered no earlier than the first
birthday, >99% of persons who receive two doses of measles vaccine develop sero-
logic evidence of measles immunity (54 )(CDC, unpublished data). Although
vaccination produces lower antibody levels than natural disease, both serologic and
epidemiologic evidence indicate that the vaccine induces long-term—probably life-
long—immunity, in most persons (55 ). Most vaccinated persons who appear to lose
antibody show an anamnestic immune response upon revaccination, indicating
that they are probably still immune (56 ). Although revaccination elicits increased
antibody levels in some persons, these increased levels may not be sustained
(57 ). Findings of some studies indicate that immunity can wane after successful
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vaccination (secondary vaccine failure), but this phenomenon appears to occur rarely
and to have little effect on measles transmission and the occurrence of outbreaks
(55,58,59 ).
Rubella Component
The live rubella virus vaccine currently distributed in the United States is prepared
in human diploid cell culture. This vaccine, containing virus strain RA 27/3, was li-
censed in the United States in January, 1979 and replaced previous rubella vaccines
(e.g., HPV-77 and Cendehill) because it induced an increased and more persistent an-
tibody response and was associated with fewer adverse events.
In clinical trials, ≥95% of susceptible persons aged ≥12 months who received a sin-
gle dose of strain RA 27/3 rubella vaccine developed serologic evidence of immunity
(60–62 ). Clinical efficacy and challenge studies indicate that >90% of vaccinated per-
sons have protection against both clinical rubella and viremia for at least 15 years
(63–66 ). Follow-up studies indicate that one dose of vaccine confers long-term—
probably lifelong—protection (67 ). Although antibody titers induced by the vaccine
are generally lower than those stimulated by rubella infection, vaccine-induced immu-
nity protects, in nearly all instances, against both clinical illness and viremia after
natural exposure (68,69 ). In studies that attempted artificial reinfection of persons
who received RA 27/3 vaccine, resistance to reinfection was similar to the resistance
that follows natural infection (70 ). However, several reports indicate that viremic rein-
fection following exposure may occur among vaccinated persons who have low levels
of detectable antibody (64 ). The frequency and consequences of this phenomenon
are unknown but it is believed to be uncommon. Clinical reinfection and fetal infection
among persons who developed immunity as a consequence of infection with wild
virus have been documented, but are apparently rare (71 ). Rarely, clinical reinfection
and fetal infection have been reported among women with vaccine-induced immunity.
Rare cases of CRS have occurred among infants born to mothers who had docu-
mented serologic evidence of rubella immunity before they became pregnant.
Mumps Component
The only mumps vaccine now available in the United States is a live virus vaccine
(Jeryl-Lynn strain) that is prepared in chick-embryo cell culture. The vaccine produces
a subclinical, noncommunicable infection with very few side effects.
More than 97% of persons who are susceptible to mumps develop measurable an-
tibody following vaccination and, in controlled clinical trials, one dose of vaccine was
approximately 95% efficacious in preventing mumps disease (72–74 ). However, field
studies have documented lower estimates of vaccine efficacy, ranging from 75% to
95% (47,75 ). Antibody levels induced by the vaccine are lower than antibody levels
resulting from natural infection (72,76,77 ). The duration of vaccine-induced immunity
is unknown, but serologic and epidemiologic data collected during 30 years of live
vaccine use indicate both the persistence of antibody and continuing protection
against infection (33,78,79 ).
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Vaccine Shipment and Storage
Administration of improperly stored vaccine may fail to provide protection against
disease from measles, rubella, and/or mumps. These live virus vaccines are supplied
in lyophilized form and should be stored at 2–8 C (35.6–46.4 F) or colder. They must be
shipped at 10 C (50 F) or colder and may be shipped on dry ice. The vaccines must be
protected from light, which may inactivate the vaccine viruses. Reconstituted vaccine
also must be protected from light, must be stored at 2–8 C (35.6–46.4 F), and must not
be frozen. Reconstituted vaccine must be discarded if not used within 8 hours.
VACCINE USAGE
Two doses of MMR vaccine separated by at least 1 month (i.e., a minimum of
28 days) and administered on or after the first birthday are recommended for all chil-
dren and for certain high-risk groups of adolescents and adults. The recommended
1 month interval between successive doses of MMR or other measles-containing vac-
cine is based on the principle that live virus vaccines not administered at the same
time should be separated by at least 1 month (80 ).
MMR is the vaccine of choice when protection against any of these three diseases
is required on or after the first birthday, unless any of its component vaccines is con-
traindicated. The purpose of the two-dose vaccination schedule is to produce
immunity in the small proportion of persons who fail to respond immunologically to
one or more of the components of the first dose. Studies indicate that two doses of
measles vaccine are necessary to develop adequate population immunity to prevent
measles outbreaks among school-aged and older persons. Mumps can occur in highly
vaccinated populations; in these outbreaks, substantial numbers of cases have oc-
curred among persons who had previously received a single dose of mumps-
containing vaccine (33,81 ). Although primary rubella vaccine failure rarely occurs, the
potential consequences of failure (i.e., CRS) are substantial. 
Almost all persons who do not respond to the measles component of the first dose
of MMR vaccine will respond to the second dose (82 ) (CDC, unpublished data). Few
data regarding the immune response to the rubella and mumps components of a sec-
ond dose of MMR vaccine are available, but most persons who do not respond to the
rubella or mumps components of the first dose would be expected to respond to the
second (82–84 ) (CDC, unpublished data). The second dose is not generally considered
a booster dose because a primary immune response to the first dose provides long-
term protection. Although some persons who develop normal antibody titers in
response to a single dose of MMR vaccine will develop higher antibody titers to the
three component vaccines when administered a second dose of vaccine, these in-
creased antibody levels typically do not persist (57 ).
Use of combined MMR vaccine for both measles doses and all other indications
should provide an additional safeguard against primary vaccine failures and facilitate
elimination of rubella and CRS and continued reduction of mumps incidence. Data
also indicate that the favorable benefit/cost ratio for routine measles, rubella, and
mumps vaccination is even greater when the vaccines are administered as combined
MMR vaccine (85,86 ).
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Dosage and Route of Administration
The lyophilized live MMR vaccine (and its component vaccines) should be reconsti-
tuted and administered as recommended by the manufacturer. All measles-, rubella-,
or mumps-containing vaccines available in the United States should be administered
subcutaneously in the recommended standard single-dose volume of 0.5 mL.
Simultaneous Administration of Vaccines
In general, simultaneous administration of the most widely used live and inacti-
vated vaccines does not impair antibody responses or increase rates of adverse
reactions (80 ). The antibody responses of persons vaccinated with MMR are similar to
those of persons vaccinated with single-antigen measles, mumps, and rubella vac-
cines at different sites or at different times.
ACIP encourages routine simultaneous administration of MMR, diphtheria and
tetanus toxoids and acellular pertussis (DTaP) or diphtheria and tetanus toxoids and
whole-cell pertussis (DTP) vaccine, Haemophilus influenzae type b (Hib) vaccine, and
oral poliovirus vaccine (OPV) or inactivated poliovirus vaccine (IPV) to children who
are at the recommended age to receive these vaccines. Antibody responses were
equivalent and no clinically significant increases in the frequency of adverse events
occurred when MMR vaccine, DTaP (or DTP), Hib vaccine, hepatitis B vaccine, and IPV
or OPV were administered either simultaneously at different sites or at separate times
(87 ). Likewise, seroconversion rates, antibody levels, and frequencies of adverse re-
actions were similar in two groups, one of which was administered MMR and varicella
vaccines simultaneously at separate sites and the other of which received the vaccines
6 weeks apart (88 )(Merck Research Laboratories, unpublished data).
Live measles and yellow fever vaccines can be administered simultaneously at
separate anatomical sites in separate syringes (89 ). Limited data also indicate that the
immunogenicity and safety of inactivated Japanese encephalitis vaccine are not com-
promised by simultaneous administration with live measles vaccine (90 ). Limited
data exist concerning concurrent administration of MMR vaccine and other vaccines
that are often recommended for international travelers (e.g., meningococcal vaccine,
typhoid vaccines). However, neither theoretical considerations nor practical experi-
ence indicate that the simultaneous administration at separate anatomic sites of MMR
and other live or inactivated vaccines will produce a diminished immune response or
increase the incidence of adverse events among vaccinated persons.
DOCUMENTATION OF IMMUNITY
Only doses of vaccine for which written documentation of the date of administra-
tion is presented should be considered valid. Neither a self-reported dose nor a history
of vaccination provided by a parent is, by itself, considered adequate documentation.
No health-care worker should provide a vaccination record for a patient unless
that health-care worker has administered the vaccine or has seen a record that docu-
ments vaccination. Persons who may be immune to measles, mumps, or rubella
but who lack either adequate documentation of vaccination or other acceptable evi-
dence of immunity (Table 1) should be vaccinated. Vaccination status and date of
















TABLE 1. Acceptable presumptive evidence of immunity to measles, rubella, and mumps
Routine
Persons who work in
health-care facilities* International travelers
Students at post-high school
educational institutions




- preschool-aged children and,
adults not at high risk: 1 dose 




(2) laboratory evidence of
immunity, or 
(3) born before 1957, or
(4) documentation of physician-
diagnosed measles
(1) documented administration




(2) laboratory evidence of
immunity, or 
(3) born before 1957
§¶
, or
(4) documentation of physician-
diagnosed measles
(1) documented administration




(2) laboratory evidence of
immunity, or 
(3) born before 1957, or
(4) documentation of physician-
diagnosed measles
(1) documented administration




(2) laboratory evidence of
immunity, or 
(3) born before 1957, or
(4) documentation of physician-
diagnosed measles
Rubella (1) documented administration




(2) laboratory evidence of
immunity, or 
(3) born before 1957 (except
women of childbearing age








(2) laboratory evidence of
immunity, or 
(3) born before 1957 (except
women of childbearing age








(2) laboratory evidence of
immunity, or 
(3) born before 1957 (except
women of childbearing age








(2) laboratory evidence of
immunity, or 
(3) born before 1957 (except
women of childbearing age
who could become pregnant
††
)
Mumps (1) documented administration




(2) laboratory evidence of
immunity, or 
(3) born before 1957, or
(4) documentation of physician-
diagnosed mumps
(1) documented administration




(2) laboratory evidence of
immunity, or 
(3) born before 1957, or
(4) documentation of physician-
diagnosed mumps
(1) documented administration




(2) laboratory evidence of
immunity, or 
(3) born before 1957, or
(4) documentation of physician-
diagnosed mumps
(1) documented administration




(2) laboratory evidence of
immunity, or 
(3) born before 1957, or
(4) documentation of physician-
diagnosed mumps
 * Health-care workers include all persons (i.e., medical or nonmedical, paid or volunteer, full- or part-time, student or nonstudent, with or without patient-care responsibilities) who
work facilities that provide health care to patients (i.e., inpatient and outpatient, private and public). Facilities that provide care exclusively for elderly patients who are at minimal
risk for measles and rubella and complications of these diseases are a possible exception.
†
The first dose should be administered on or after the first birthday; the second dose of measles-containing vaccine should be administered no earlier than one month (i.e.,
minimum of 28 days) after the first dose. Combined measles-mumps-rubella (MMR) vaccine generally should be used whenever any of its component vaccines is indicated.
§
May vary depending on current state or local requirements.
¶
Health-care facilities should consider recommending a dose of MMR vaccine for unvaccinated workers born before 1957 who are at risk for occupational exposure to measles
and who do not have a history of measles disease or laboratory evidence of measles immunity.
** Children aged 6–11 months should receive a dose of monovalent measles vaccine (or MMR, if monovalent vaccine is not available) before departure. Children who receive a
dose of measles-containing vaccine before their first birthdays should be revaccinated with two doses of MMR vaccine, the first of which should be administered when the child
is aged 12–15 months (12 months if the child remains in a high-risk area) and the second at least 28 days later.
††
Women of childbearing age are adolescent girls and premenopausal adult women. Because rubella can occur in some persons born before 1957 and because congenital rubella
and congenital rubella syndrome can occur in the offspring of women infected with rubella virus during pregnancy, birth before 1957 is not acceptable evidence of rubella
immunity for women who could become pregnant.
administration of all vaccinations should be documented in the patient’s permanent
medical record.
Serologic screening for measles, rubella, or mumps immunity generally is neither
necessary nor recommended if a person has other acceptable evidence of immunity
to the disease (Table 1). Serologic screening can be a barrier to vaccination. With the
exception of women who are known to be pregnant (see Women of Childbearing
Age), persons who lack acceptable evidence of immunity generally should be vacci-
nated without serologic testing. Serologic screening is appropriate only when persons
identified as susceptible are subsequently vaccinated in a timely manner. Screening is
most applicable when the return and vaccination of those tested can be ensured (e.g.,
hiring of new health-care workers). If these conditions are not met, serologic screen-
ing is inappropriate (91 ). Likewise, during an outbreak of measles, rubella, or mumps,
serologic screening before vaccination generally is not recommended because wait-
ing for results, contacting, and then vaccinating persons identified as susceptible can
impede the rapid vaccination needed to curb the outbreak.
Serologic screening for antibodies to measles, rubella, or mumps alone will not
identify persons who are susceptible to the other diseases for which screening is not
done. Post-vaccination serologic testing to verify an immune response to MMR or its
component vaccines is not recommended.
The criteria for acceptable evidence of immunity to measles, rubella, and mumps
(Table 1) provide presumptive rather than absolute evidence of immunity. Occasion-
ally, a person who meets the criteria for presumptive immunity can contract and
transmit disease. Specific criteria for documentation of immunity have been estab-
lished for certain persons (e.g., health-care workers, international travelers, and
students at post-high school educational institutions) who are at increased risk for
exposure to measles, rubella, and mumps (Table 1). Criteria accepted as evidence of
immunity for the purpose of meeting school or college entry requirements or other
government regulations may vary among state and local jurisdictions.
Measles
Persons generally can be presumed immune to measles (Table 1) if they have docu-
mentation of adequate vaccination, laboratory evidence of immunity to measles,
documentation of physician-diagnosed measles, or were born before 1957. Criteria for
adequate vaccination currently vary depending on state and local vaccination policy
because of differences in the way states have implemented the two-dose measles vac-
cination schedule. All states are strongly encouraged to take immediate steps to
implement the two-dose MMR vaccination schedule so that, by 2001, adequate vacci-
nation of children will be defined in all 50 states as follows:
• For preschool-aged children: documentation of at least one dose of MMR vaccine
administered on or after the first birthday.
• For children in kindergarten through grade 12: documentation of two doses
of MMR vaccine separated by at least 28 days (i.e., 1 month), with the first
dose administered no earlier than the first birthday. 
Doses of MMR and other measles-containing vaccines administered before the first
birthday should not be counted when determining adequacy of measles vaccination.
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When measles virus is introduced into a community, persons who work in health-
care facilities are at greater risk for acquiring measles than the general population
(92 ). Because persons working in medical settings have been infected with and have
transmitted measles to patients and coworkers, rigorous criteria for immunity among
health-care workers have been established. For persons born during or after 1957 who
work in health-care facilities, adequate vaccination consists of two doses of MMR
or other live measles-containing vaccine separated by at least 28 days, with the first
dose administered no earlier than the first birthday (Table 1). In addition, although
birth before 1957 is generally considered acceptable evidence of measles immunity
(Table 1), measles has occurred in some unvaccinated persons born before 1957 who
worked in health-care facilities. Therefore, health-care facilities should consider rec-
ommending a dose of MMR vaccine for unvaccinated workers born before 1957 who
lack a history of measles disease or laboratory evidence of measles immunity (see
Health-Care Facilities).
The previously described criteria apply only to routine vaccination. During measles
outbreaks, evidence of adequate vaccination for school-aged children, adolescents,
and adults born during or after 1957 who are at risk for measles exposure and infec-
tion consists of two doses of measles-containing vaccine separated by at least
28 days, with the first dose administered no earlier than the first birthday (see Measles
Outbreak Control). During outbreaks involving preschool-aged children, authorities
should consider extending this criterion to all children aged ≥12 months.
In the past, the most commonly used laboratory test for assessing immunity to
measles was the hemagglutination-inhibition (HI) test but more sensitive assays (e.g.,
the enzyme immunoassay [EIA] or enzyme-linked immunosorbent assay [ELISA]) are
now used in most laboratories. Persons who have measles-specific antibody that is
detectable by any serologic test are considered immune. Persons with an “equivocal”
test result should be considered susceptible unless they have other evidence of mea-
sles immunity (Table 1) or subsequent testing indicates they are immune. All new
cases of suspected measles should be confirmed by laboratory testing (see Measles
Case Investigation—Laboratory Diagnosis).
Rubella
Persons generally can be presumed immune to rubella (Table 1) if they have docu-
mentation of vaccination with at least one dose of MMR or other live rubella-
containing vaccine administered on or after the first birthday, laboratory evidence of
rubella immunity, or were born before 1957 (except women who could become preg-
nant). Birth before 1957 is not acceptable evidence of rubella immunity for women
who could become pregnant because it provides only presumptive evidence of ru-
bella immunity and does not guarantee that a person is immune (see Women of
Childbearing Age). Rubella can occur among some unvaccinated persons born before
1957 and congenital rubella and CRS can occur among the offspring of women in-
fected with rubella during pregnancy.
Persons who have an “equivocal” serologic test result should be considered sus-
ceptible to rubella unless they have evidence of adequate vaccination or a subsequent
serologic test result indicates rubella immunity. Although only one dose of rubella-
containing vaccine is required as acceptable evidence of immunity to rubella, children
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should receive two doses of MMR vaccine. The first dose is administered routinely
when the child is aged 12–15 months and the second before the child enters school
(i.e., at age 4–6 years)(see Routine Vaccination).
The clinical diagnosis of rubella is unreliable and should not be considered in as-
sessing immune status. Because many rash illnesses may mimic rubella infection and
many rubella infections are unrecognized, the only reliable evidence of previous ru-
bella infection is the presence of serum rubella immunoglobulin G (IgG). Laboratories
that regularly perform antibody testing generally provide the most reliable results be-
cause their reagents and procedures are more likely to be strictly standardized (see
Rubella Case Investigation and Outbreak Control).
Postinfection immunity to rubella appears to be long-lasting and is probably
lifelong. However, as with other viral diseases, re-exposure to natural rubella occa-
sionally leads to reinfection without clinical illness or detectable viremia. The risk for
CRS among infants born to women reinfected with rubella during pregnancy is mini-
mal (93,94 ). Although data from several studies indicate that levels of vaccine-
induced rubella antibodies may decline with time, data from surveillance of rubella
and CRS suggest that waning immunity with increased susceptibility to rubella dis-
ease does not occur (28 )(CDC, unpublished data).
HI antibody testing was formerly the method most frequently used to screen for
rubella antibodies. However, the HI test has been supplanted by other assays of equal
or greater sensitivity. EIAs are the most commonly used of these newer commercial
assays, but latex agglutination, immunofluorescence assay (IFA), passive hemaggluti-
nation, hemolysis-in-gel, and virus neutralization tests are also available.
Any antibody level above the standard positive cutoff value of the assay with which
it is measured can be considered evidence of immunity, if the assay is licensed. When
serum specimens from adults who did not produce antibodies detectable by HI after
vaccination were examined with an equivalently specific but more sensitive test, al-
most all had detectable antibody (95,96 ). A few children who initially developed
antibody detectable by HI apparently “lost” this antibody during follow-up intervals of
up to 16 years (77,97,98 ). However, almost all had antibody detectable by more sensi-
tive tests. In several of these cases, immunity was confirmed by documenting a
booster response (i.e., absence of IgM antibody and a rapid rise in IgG antibody) after
revaccination (62,99 ).
Occasionally, persons with documented histories of rubella vaccination have ru-
bella serum IgG levels that are not clearly positive by ELISA. Such persons can be
administered a dose of MMR vaccine and need not be retested for serologic evidence
of rubella immunity.
Mumps
Persons generally can be presumed immune to mumps (Table 1) if they have docu-
mentation of vaccination with live mumps virus vaccine on or after the first birthday,
laboratory evidence of mumps immunity, documentation of physician-diagnosed
mumps, or were born before 1957. 
The demonstration of mumps IgG antibody by any commonly used serologic assay
is acceptable evidence of mumps immunity. Persons who have an “equivocal” sero-
logic test result should be considered susceptible to mumps unless they have other
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evidence of mumps immunity (Table 1) or subsequent testing indicates they are im-
mune. All new cases of suspected mumps should be confirmed by an appropriate
serologic assay (see Mumps Case Investigation, Laboratory Diagnosis).
Live mumps vaccine was not used routinely before 1977. Before the vaccine was
introduced, the age-specific incidence of the disease peaked among children aged 5–
9 years. Therefore, most persons born before 1957 are likely to have been infected
naturally between 1957 and 1977 and may be presumed immune, even if they have
not had clinically recognizable mumps disease. However, birth before 1957 does not
guarantee mumps immunity. Therefore, during mumps outbreaks, MMR vaccination
should be considered for persons born before 1957 who may be exposed to mumps
and who may be susceptible. Laboratory testing for mumps susceptibility before vac-
cination is not necessary.
ROUTINE VACCINATION
Preschool-Aged Children
Children should receive the first dose of MMR vaccine at age 12–15 months (i.e., on
or after the first birthday). In areas where risk for measles is high, initial vaccination
with MMR vaccine is recommended for all children as soon as possible upon reaching
the first birthday (i.e., at age 12 months). An area where measles risk is high is defined
as: 
• a county with a large inner city population,
• a county where a recent measles outbreak has occurred among unvaccinated
preschool-aged children, or
• a county in which more than five cases of measles have occurred among pre-
school-aged children during each of the last 5 years. 
These recommendations may be implemented for an entire county or only within
defined areas of a county. This strategy assumes that the benefit of preventing mea-
sles cases among children aged 12–15 months outweighs the slightly reduced efficacy
of the vaccine when administered to children aged <15 months. In addition, almost all
children who do not respond immunologically to the first dose of MMR vaccine will
develop measles immunity after receiving a second dose. HIV-infected children should
receive MMR vaccine at age 12 months, if not otherwise contraindicated (see Special
Considerations for Vaccination—Persons Infected with Human Immunodeficiency Vi-
rus (HIV)).
School-Aged Children and Adolescents
The second dose of MMR vaccine is recommended when children are aged 4–
6 years (i.e., before a child enters kindergarten or first grade). This recommended
timing for the second dose of MMR  vaccine has been adopted jointly by ACIP, the
American Academy of Pediatrics (AAP), and the American Academy of Family Physi-
cians (AAFP). Evidence now indicates that a) the major benefit of administering the
second dose is a reduction in the proportion of persons who remain susceptible
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because of primary vaccine failure, b) waning immunity is not a major cause of vac-
cine failure and has little influence on measles transmission, and c) revaccination of
children who have low levels of measles antibody produces only a transient rise in
antibody levels (55,57–59,100,101 ).
Because approximately 5% of children who receive only one dose of MMR vaccine
fail to develop immunity to measles, ACIP recommends that all states implement a
requirement that all children entering school have received two doses of MMR vac-
cine (with the first dose administered no earlier than the first birthday) or have other
evidence of immunity to measles, rubella, and mumps (see Documentation of Immu-
nity). In addition, to achieve complete immunization of all school-aged children and
hasten progress toward measles elimination, states are strongly encouraged to take
immediate steps to ensure that, by 2001, all children in grades kindergarten through
12 have received two doses of MMR vaccine.
As part of comprehensive health services for all adolescents, ACIP, AAP, and AAFP
recommend a health maintenance visit at age 11–12 years. This visit should serve as
an opportunity to evaluate vaccination status and administer MMR vaccine to all per-
sons who have not received two doses at the recommended ages.
Children who do not have documentation of adequate vaccination against measles,
rubella, and mumps or other acceptable evidence of immunity to these diseases (see
Documentation of Immunity) should be admitted to school only after administration
of the first dose of MMR vaccine. If required, the second MMR dose should be admin-
istered as soon as possible, but no sooner than 28 days after the first dose. Children
who have already received two doses of MMR vaccine at least 1 month apart, with the
first dose administered no earlier than the first birthday, do not need an additional
dose when they enter school. 
Adults
Persons born in 1957 or later who are aged ≥18 years and who do not have a medi-
cal contraindication should receive at least one dose of MMR vaccine unless they have
a) documentation of vaccination with at least one dose of measles-, rubella-, and
mumps- containing vaccine or b) other acceptable evidence of immunity to these
three diseases (Table 1). Persons born before 1957 generally can be considered im-
mune to measles and mumps. In addition, persons born before 1957, except women
who could become pregnant, generally can be considered immune to rubella. 
MMR vaccine (one dose or two doses administered at least 28 days apart) may be
administered to any person born before 1957 for whom the vaccine is not contraindi-
cated. Adults who may be at increased risk for exposure to and transmission of
measles, mumps, and rubella should receive special consideration for vaccination.
These persons include international travelers, persons attending colleges and other
post-high school educational institutions, and persons who work at health-care facili-
ties. In addition, all women of childbearing age should be considered susceptible to
rubella unless they have received at least one dose of MMR or other live rubella virus
vaccine on or after the first birthday or have serologic evidence of immunity. Vaccina-
tion recommendations for these high-risk groups follow.
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Women of Childbearing Age
MMR vaccine should be offered to all women of childbearing age (i.e., adolescent
girls and premenopausal adult women) who do not have acceptable evidence of
rubella immunity whenever they make contact with the health-care system. Opportu-
nities to vaccinate susceptible women include occasions when their children undergo
routine examinations or vaccinations. The continuing occurrence of rubella among
women of childbearing age indicates the need to continue vaccination of susceptible
adolescent and adult women of childbearing age, and the absence of evidence of vac-
cine teratogenicity indicates that the practice is safe (102 ). Vaccination of susceptible
women of childbearing age should
• be part of routine general medical and gynecologic outpatient care;
• take place in all family-planning settings; and
• be provided routinely before discharge from any hospital, birthing center, or
other medical facility, unless a specific contraindication exists (see Precautions
and Contraindications). 
Outbreaks of rubella in the United States recently have occurred among women of
Hispanic ethnicity, many of whom were born outside the fifty states. Efforts should be
made to ensure that all susceptible women of childbearing age, especially those who
grew up outside the fifty states in areas where routine rubella vaccination may not
occur, are vaccinated with MMR vaccine or have other acceptable evidence of immu-
nity (Table 1). Ascertainment of rubella-immune status of women of childbearing age
and the availability of rubella vaccination should be components of the health-care
program in places where the risks for disease exposure and transmission are substan-
tial (e.g., day care facilities, schools, colleges, jails, and prisons).
No evidence indicates that administration of rubella-containing vaccine virus to a
pregnant woman presents a risk for her fetus, although such a risk cannot be excluded
on theoretical grounds. Therefore, women of childbearing age should receive rubella-
containing vaccines (i.e., rubella, MR, or MMR vaccine) only if they state that they are
not pregnant and only if they are counseled not to become pregnant for 3 months after
vaccination. Because of the importance of protecting women of childbearing age
against rubella, reasonable practices in any immunization program include a) asking
women if they are pregnant, b) not vaccinating women who state that they are preg-
nant, c) explaining the potential risk for the fetus to women who state that they are not
pregnant, and d) counseling women who are vaccinated not to become pregnant dur-
ing the 3 months following MMR vaccination.
Routine Vaccination of Women Who Are Not Pregnant. Women of childbearing age
who do not have documentation of rubella vaccination or serologic evidence of ru-
bella immunity should be vaccinated with MMR, if they have no contraindications to
the vaccine. Birth before 1957 is not acceptable evidence of immunity for women who
could become pregnant (Table 1). The use of MMR vaccine provides the potential ad-
ditional benefit of protection against measles and mumps. Serologic testing before
vaccination is not necessary and might present a barrier to timely vaccination. Routine
testing for rubella antibody during clinic visits for routine health care, premarital
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evaluation, family planning, or diagnosis and treatment of sexually transmitted dis-
eases may identify women who are not immune to rubella before they become
pregnant. Such routine serologic testing is not useful unless it is linked to timely fol-
low-up and vaccination of women who are susceptible (103 ).
Prenatal Screening and Postpartum Vaccination. Prenatal serologic screening of
women who have acceptable evidence of rubella immunity is generally not necessary,
but is indicated for all pregnant women who lack acceptable evidence of rubella im-
munity (Table 1). Upon completion or termination of their pregnancies, women who
do not have serologic evidence of rubella immunity or documentation of rubella vac-
cination should be vaccinated with MMR before discharge from the hospital, birthing
center, or abortion clinic (104 ). They should be counseled to avoid conception for
3 months after vaccination. Postpartum rubella vaccination of all women not known to
be immune could prevent up to half of CRS cases (105–108 ) ( CDC, unpublished data).
Colleges and Other Post-High School Educational Institutions
Risks for transmission of measles, rubella, and mumps at post-high school educa-
tional institutions can be high because these institutions may bring together large
concentrations of persons susceptible to these diseases (109–113 ). Therefore, col-
leges, universities, technical and vocational schools, and other institutions for
post-high school education should require that all undergraduate and graduate stu-
dents have received two doses of MMR vaccine or have other acceptable evidence of
measles, rubella, and mumps immunity (Table 1) before enrollment.
College entry requirements for measles immunity substantially reduce the risk for
measles outbreaks on college campuses where they are implemented and enforced
(111 ). State requirements for pre-enrollment vaccination ensure the best protection
against widespread measles transmission among students at college campuses and
other post-high school educational institutions. States are strongly encouraged to
adopt such regulations. Students who do not have documentation of live measles,
rubella, or mumps vaccination or other acceptable evidence of immunity at the time
of enrollment (Table 1) should be admitted to classes only after receiving the first dose
of MMR vaccine. These students should be administered a second dose of MMR vac-
cine 1 month (i.e., at least 28 days) later. Students who have documentation of having
received only one dose of measles-containing vaccine on or after the first birthday
should receive a second dose of MMR before enrollment, provided at least 1 month
has elapsed since the previous dose. Students who have a medical contraindication to
receiving any of the components of MMR vaccine should be given a letter of explana-
tion to present to the health officials of their educational institution.
Health-Care Facilities
When measles virus is introduced into a community, persons who work in health-
care facilities are at increased risk for acquiring measles compared with the general
population (92,114,115 ). During 1985–1991, at least 795 measles cases (1.1% of all
reported cases) occurred among adult health-care workers. Of these, 29% occurred
among nurses, 15% among physicians, 11% among persons in other health-care
occupations (e.g., laboratory and radiology technicians, etc.), 11% among clerks,
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4% among nursing assistants, and 4% among medical and nursing students (115 )
(CDC, unpublished data). A general decline in measles incidence occurred after 1991.
However, 15 of the 75 measles outbreaks reported during 1993–1996 involved trans-
mission in a medical facility, and a total of 36 measles cases (1.8% of all reported
cases) occurred among persons working in health-care facilities (CDC, unpublished
data). Although similar surveillance data are not available for rubella, outbreaks have
occurred in health-care settings, and health-care workers have transmitted rubella to
patients (116 ) (CDC, unpublished data).
All persons who work in health-care facilities should be immune to measles and
rubella (Table 1). Because any health-care worker (i.e., medical or nonmedical, paid or
volunteer, full- or part-time, student or nonstudent, with or without patient-care re-
sponsibilities) who is not immune to measles and rubella can contract and transmit
these diseases, all health-care facilities (i.e., inpatient and outpatient, private and pub-
lic) should ensure that those who work in their facilities are immune to measles and
rubella (Table 1)*.
Health-care workers have a responsibility to avoid transmitting these diseases and
thereby causing harm to patients. Adequate vaccination for health-care workers born
during or after 1957 consists of two doses of a live measles-containing vaccine and at
least one dose of a live rubella-containing vaccine (Table 1). Health-care workers who
need a second dose of measles-containing vaccine should be revaccinated 1 month
(at least 28 days) after their first dose.
Although birth before 1957 is generally considered acceptable evidence of measles
and rubella immunity (Table 1), health-care facilities should consider recommending a
dose of MMR vaccine to unvaccinated workers born before 1957 who do not have a
history of physician-diagnosed measles or laboratory evidence of measles immunity
AND laboratory evidence of rubella immunity. 
Rubella vaccination or laboratory evidence of rubella immunity is particularly im-
portant for female health-care workers who could become pregnant, including those
born before 1957. In addition, during rubella outbreaks, health-care facilities should
strongly consider recommending a dose of MMR vaccine to unvaccinated health-care
workers born before 1957 who do not have serologic evidence of immunity. Serologic
surveys of hospital workers indicate that 5%–9% of those born before 1957 do not
have detectable measles antibody (117,118 ) and about 6% do not have detectable
rubella antibody (119 ). In addition, during 1985–1992, 643 measles cases were re-
ported among health-care workers whose year of birth was known; 27% of these
persons were born before 1957 (CDC, unpublished data). Comparable surveillance
data are not available for rubella.
Serologic screening need not be done before vaccinating for measles and rubella
unless the medical facility considers it cost-effective (91,120,121 ). Serologic testing is
appropriate only if persons who are identified as susceptible are subsequently vacci-
nated in a timely manner. Serologic screening ordinarily is not necessary for persons
who have documentation of appropriate vaccination or other acceptable evidence of
immunity (Table 1). During outbreaks of measles or rubella, serologic screening
before vaccination is not generally recommended because rapid vaccination is neces-
sary to halt disease transmission.
*Facilities that provide care exclusively for elderly patients who are at minimal risk for measles
and rubella and complications of these diseases are a possible exception.
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Transmission of mumps has occurred in medical settings (122 ). Therefore, immu-
nity to mumps is highly desirable for all health-care workers (Table 1). Adequate
mumps vaccination for health-care workers born during or after 1957 consists of one
dose of live mumps-containing vaccine.
MMR vaccine generally should be used whenever any of its component vaccines is
indicated. However, if the prospective vaccinee has acceptable evidence of immunity
to one or two of the components of MMR vaccine (Table 1), a monovalent or bivalent
vaccine can be used.
International Travel
Measles, rubella, and mumps are endemic in many countries. Protection against
measles is especially important for persons planning foreign travel, including adoles-
cents and adults who have not had measles disease and have not been adequately
vaccinated, and infants aged 6–11 months. Similarly, protection against rubella is es-
pecially important for women of childbearing age who are not immune to the disease.
Although proof of vaccination is not required for entry into the United States, persons
traveling or living abroad should ensure that they are immune to measles, rubella, and
mumps.
Persons who travel or live abroad and who do not have acceptable evidence
of measles, rubella, and mumps immunity (Table 1) should be vaccinated with MMR.
Children who travel or live abroad should be vaccinated at an earlier age than recom-
mended for children remaining in the United States. Before their departure from the
United States, children aged ≥12 months should have received two doses of MMR
vaccine separated by at least 28 days, with the first dose administered on or after the
first birthday. Children aged 6–11 months should receive a dose of monovalent mea-
sles vaccine before departure. If monovalent measles vaccine is not available, no
specific contraindication exists to administering MMR to children aged 6–11 months.
However, because the risk for serious disease from either mumps or rubella infection
among infants is relatively low and because children aged <12 months are less likely
to develop serologic evidence of immunity when vaccinated with measles, mumps,
and rubella antigens than are older children, mumps vaccine and rubella vaccine gen-
erally are administered only to children aged ≥12 months. Children administered
monovalent measles vaccine or MMR before the first birthday should be considered
potentially susceptible to all three diseases and should be revaccinated with two
doses of MMR, the first of which should be administered when the child is aged 12–
15 months (12 months if the child remains in an area where disease risk is high) and
the second at least 28 days later.
Parents who travel or reside abroad with infants aged <12 months should have
acceptable evidence of immunity to rubella and mumps (Table 1), as well as measles,
so they will not become infected if their infants contract these diseases. Infants aged
<6 months are usually protected against measles, rubella, and mumps by maternally
derived antibodies and ordinarily do not require additional protection unless the in-
fant’s mother is diagnosed with measles (see Use of Vaccine and Immune Globulin
Among Persons Exposed to Measles, Rubella, or Mumps).
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SPECIAL CONSIDERATIONS FOR VACCINATION
Persons Infected with Human Immunodeficiency Virus (HIV)
Although the risk for measles exposure is currently low in most areas of the United
States and the Western Hemisphere, this risk remains high in many other regions and
measles continues to be imported into the United States. HIV-infected persons are at
increased risk for severe complications if infected with measles (126,127 ). Among
HIV-infected persons who did not have evidence of severe immunosuppression
(Table 2), no serious or unusual adverse events have been reported after measles vac-
cination (123–126 ). Therefore, MMR vaccination is recommended for all asymp-
tomatic HIV- infected persons who do not have evidence of severe immunosuppres-
sion and for whom measles vaccination would otherwise be indicated. MMR vac-
cination should also be considered for all symptomatic HIV-infected persons who do
not have evidence of severe immunosuppression (Table 2) (128,129 ). Testing asymp-
tomatic persons for HIV infection is not necessary before administering MMR or other
measles-containing vaccine (130 ).
Transient increases in HIV viral load have been observed after administration of
other vaccines to HIV-infected persons (131,132 ). The clinical significance of these
increases is not known. Theoretically, a similar increase also may occur after MMR
vaccination of HIV-infected persons. 
Because the immunologic response to live and killed-antigen vaccines may de-
crease as HIV disease progresses, vaccination early in the course of HIV infection may
be more likely to induce an immune response (133 ). Therefore, HIV-infected infants
without severe immunosuppression should routinely receive MMR vaccine as soon as
possible upon reaching the first birthday (i.e., at age 12 months)(130 ). Consideration
should be given to administering the second dose of MMR vaccine as soon as 28 days
(i.e., 1 month) after the first dose rather than waiting until the child is ready to enter
kindergarten or first grade. In addition, if at risk for exposure to measles, HIV-infected
infants who are not severely immunocompromised should be administered single-
antigen measles vaccine or MMR vaccine at age 6–11 months. These children should
receive another dose, administered as MMR vaccine, as soon as possible upon reach-
ing the first birthday, provided at least 1 month has elapsed since the administration
TABLE 2. Age-specific CD4+ T-lymphocye count and percent of total lymphocytes as
criteria for severe immunosuppression in persons infected with human
immunodeficiency virus (HIV)
Age
<12 mos 1–5 yrs 6–12 yrs ≥13 yrs
Total CD4+ T-lymphocytes
               OR















CDC. 1993 Revised classification system for HIV infection and expanded surveillance case
definition for AIDS among adolescents and adults. MMWR 1992;41(RR-17):1–19. (125 )
CDC. 1994 Revised classification system for human immunodeficiency virus infection in children
less than 13 years of age; official authorized addenda: human immunodeficiency virus infection
codes and official guidelines for coding and reporting ICD-9-CM. MMWR 1994; 43(RR-12):1–19.
(126 )
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of the previous dose of measles-containing vaccine. An additional dose of MMR vac-
cine can be administered as early as 1 month after the second dose. If otherwise
indicated, newly diagnosed HIV-infected children and adults without acceptable evi-
dence of measles immunity (Table 1) should receive MMR vaccine as soon as possible
after diagnosis, unless they have evidence of severe immunosuppression (Table 2).
Data indicate that, of the HIV-infected infants born in the United States annually,
approximately 5% (i.e., 50 children per year) would be classified as severely immuno-
compromised at age 12 months, when the first dose of MMR vaccine is
recommended.
Measles vaccine is not recommended for HIV-infected persons with evidence of
severe immunosuppression (Table 2) for several reasons: 
• a case of progressive measles pneumonitis occurred in a person with AIDS and
severe immunosuppression to whom MMR vaccine was administered (134 );
• evidence indicates a diminished antibody response to measles vaccine among
severely immunocompromised HIV-infected persons (133 );
• morbidity related to measles vaccination has been reported among persons with
severe immunosuppression unrelated to HIV infection (135–138 ); and
• in the United States, the incidence of measles is presently very low.
Serious illness associated with administration of rubella or mumps vaccines to HIV-
infected persons has not been reported. MMR vaccine is not contraindicated for the
close contacts of immunocompromised persons. All family and other close contacts
of HIV-infected persons should be vaccinated with MMR vaccine, unless they have
acceptable evidence of measles immunity.
Severely immunocompromised patients and other symptomatic HIV-infected pa-
tients who are exposed to measles should receive immune globulin (IG) prophylaxis
regardless of vaccination status because they may not be protected by the vaccine.
For patients receiving intravenous immune globulin (IGIV) therapy, a standard dose of
100–400 mg/kg should be sufficient to prevent measles infection after exposures oc-
curring within 3 weeks after administration of IGIV; for patients exposed to measles
>3 weeks after receiving a standard IGIV dose, an additional dose should be consid-
ered. Although no data are available concerning the effectiveness of IGIV in pre-
venting measles, high dose IGIV may be as effective as immune globulin administered
intramuscularly. Persons receiving regular (e.g., monthly) IGIV therapy for HIV infec-
tion or other indications may not respond to MMR or its component vaccines because
of the continued presence of high levels of passively acquired antibody (see Precau-
tions and Contraindications, Recent Administration of Immune Globulin). If indicated,
MMR vaccine should be administered at least 2 weeks before beginning IGIV therapy.
Use of Vaccine and Immune Globulin Among Persons Exposed
to Measles, Rubella, or Mumps
Use of Vaccine
Exposure to measles is not a contraindication to vaccination. MMR or measles vac-
cine, if administered within 72 hours of initial measles exposure, may provide some
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protection (139–143 ). For most persons aged ≥12 months who are exposed to mea-
sles in most settings (e.g., day care facilities, schools, colleges, health-care facilities),
administration of MMR or measles vaccine is preferable to using immune globulin
(IG). For susceptible persons aged ≥6 months who are household contacts of measles
patients, use of vaccine within 72 hours of initial exposure is also acceptable. How-
ever, measles often is not recognized as such until >72 hours after onset. Therefore,
administration of IG to susceptible household contacts who are not vaccinated within
72 hours of initial exposure is recommended (see Use of Immune Globulin). Infants
vaccinated before age 12 months must be revaccinated on or after the first birthday
with two doses of MMR vaccine separated by at least 28 days (see Routine Vaccina-
tion). Measles-containing vaccine is not recommended for postexposure measles
prophylaxis in immunocompromised persons or pregnant women (see Contraindica-
tions).
Postexposure MMR vaccination does not prevent or alter the clinical severity of
rubella or mumps. However, widespread vaccination during a mumps outbreak may
help terminate such outbreaks (144 ).
If exposure to measles, rubella, or mumps does not cause infection, postexposure
vaccination with MMR should induce protection against subsequent infection. If the
exposure results in infection, no evidence indicates that administration of MMR vac-
cine during the presymptomatic or prodromal stage of illness increases the risk for
vaccine-associated adverse events.
Use of Immune Globulin
If administered within 6 days of exposure, IG can prevent or modify measles in a
nonimmune person. However, any immunity conferred is temporary unless modified
or typical measles occurs (139 ). The usual recommended dose of IG is 0.25 mL/kg
(0.11 mL/lb) of body weight (maximum dose = 15 mL). However, the recommended
dose of IG for immunocompromised persons is 0.5 mL/kg of body weight (maxi-
mum dose = 15 mL). For persons receiving IGIV therapy, administration of at least
100 mg/kg within 3 weeks before measles exposure should be sufficient to prevent
measles infection.
IG is indicated for susceptible household contacts of measles patients, particularly
those for whom the risk for complications is increased (i.e., infants aged ≤12 months,
pregnant women, or immunocompromised persons). Infants <6 months of age are
usually immune because of passively acquired maternal antibodies. However, if mea-
sles is diagnosed in a mother, unvaccinated children of all ages in the household who
lack other evidence of measles immunity should receive IG. IG prophylaxis is not indi-
cated for household contacts who have received a dose of measles vaccine on or after
the first birthday, unless they are immunocompromised. Only if administered within
72 hours of initial measles exposure is MMR vaccine acceptable for postexposure pro-
phylaxis in household contacts aged ≥6 months except pregnant women, immuno-
compromised patients, and others for whom vaccine is contraindicated (see Use of
Vaccine). IG should not be used to control measles outbreaks.
Any person exposed to measles who lacks evidence of measles immunity (Table 1)
and to whom IG is administered should subsequently receive MMR vaccine, which
should be administered no earlier than 5–6 months after IG administration, provided
the person is then aged ≥12 months and the vaccine is not otherwise contraindicated.
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TABLE 3. Suggested intervals between administration of immune globulin prep-
arations for various indications and vaccines containing live-measles virus*




Tetanus prophylaxis (TIG) 250 units (10 mg IgG/kg) IM 3
Hepatitis A prophylaxis (IG)
- Contact prophylaxis
- International travel
0.02 mL/kg (3.3 mg IgG/kg) IM
0.06 mL/kg (10 mg IgG/kg) IM
3
3
Hepatitis B prophylaxis (HBIG) 0.06 mL/kg (10 mg IgG/kg) IM 3
Rabies prophylaxis (HRIG) 20 IU/kg (22 mg IgG/kg) IM 4




- Standard (i.e., nonimmuno-
  compromised) contact
- Immunocompromised contact
0.25 mL/kg (40 mg IgG/kg) IM




- Red blood cells (RBCs), washed
- RBCs, adenine-saline added
- Packed RBCs (Hct 65%)†
- Whole blood (Hct 35%–50%)†
- Plasma/platelet products
10 mL/kg (negligible IgG/kg) IV
10 mL/kg (10 mg IgG/kg) IV
10 mL/kg (60 mg IgG/kg) IV
10 mL/kg (80–100 mg IgG/kg) IV






Replacement therapy for immune
deficiencies§
300–400 mg/kg IV (as IVIG) 8
Respiratory syncytial virus prophylaxis 750 mg/kg IV (as RSV-IGIV) 9
Immune thrombocytopenic purpura(ITP) 400 mg/kg IV (as IGIV)
1000 mg/kg IV (as IGIV)
8
10
Kawasaki disease 2 g/kg IV (as IGIV) 11
*This table is not intended for determining the correct indications and dosage for the use of
immune globulin preparations. Unvaccinated persons may not be fully protected against
measles during the entire suggested time interval, and additional doses of immune globulin
and/or measles vaccine may be indicated after measles exposure. The concentration of measles
antibody in a particular immune globulin preparation can vary by lot. The rate of antibody
clearance after receipt of an immune globulin preparation can vary. The recommended inter-
vals are extrapolated from an estimated half life of 30 days for passively acquired antibody
and an observed interference with the immune response to measles vaccine for 5 months
after a dose of 80 mg IgG/kg. (See Mason W, Takahashi M, Schneider T. Persisting passively
acquired measles antibody following gamma globulin therapy for Kawaski disease and re-
sponse to live virus vaccination. In: Program and abstracts of the 32nd meeting of the
Interscience Conference on Antimicrobial Agents and Chemotherapy [Abstract] Los Angeles
CA, October 1992.
†Assumes a serum IgG concentration of 16 mg/mL.
§Measles vaccination is recommended for HIV-infected children who do not have evidence of
severe immunosuppression, but is contraindicated for patients who have congenital disorders
of the immune system (Table 2).
Abbreviations: HBIG=hepatitis B immune globulin; Hct=hematocrit; HRIG=human rabies
immune globulin; IG=serum immune globulin; IGIV=immune globulin, intravenous;
IM=intramuscular; IV=intravenous, RBCs=red blood cells; RSV-IGIV=respiratory syncytial virus
immune globulin, intravenous; TIG=tetanus immune globulin; VZIG=varicella zoster immune
globulin.
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Passively acquired measles antibodies can interfere with the immune response to
measles vaccination (see Recent Administration of Immune Globulins). The interval
required to avoid such interference varies (Table 3).
IG does not prevent rubella or mumps infection after exposure and is not recom-
mended for that purpose. Although administration of IG after exposure to rubella
will not prevent infection or viremia, it may modify or suppress symptoms and create
an unwarranted sense of security. Therefore, IG is not recommended for routine
postexposure prophylaxis of rubella in early pregnancy or any other circumstance.
Infants with congenital rubella have been born to women who received IG shortly
after exposure. Administration of IG should be considered only if a pregnant woman
who has been exposed to rubella will not consider termination of pregnancy under
any circumstances. In such cases, intramuscular administration of 20 mL of immune
globulin within 72 hours of rubella exposure may reduce—but will not eliminate—the
risk for rubella (145,146 ). 
Revaccination of Persons Vaccinated According to Earlier
Recommendations
Some persons vaccinated according to earlier recommendations for use of mea-
sles, rubella, mumps, and MMR vaccines should be revaccinated to ensure that they
are adequately protected. Unless one of its component vaccines is contraindicated,
MMR vaccine should be used for this purpose.
Previous vaccination with live measles, rubella, and mumps vaccines. Persons vacci-
nated with live measles, rubella, or mumps vaccines before the first birthday who
were not revaccinated on or after the first birthday should be considered unvacci-
nated. Unless they have other acceptable evidence of immunity to measles, rubella,
and mumps (Table 1), these persons should be revaccinated with MMR.
Live attenuated Edmonston B measles vaccine (distributed from 1963 to 1975) was
usually administered with IG or high-titer measles immune globulin (MIG; no longer
available in the United States). Vaccination with this product, administered on or after
the first birthday, is considered an effective first dose of vaccine. If indicated, a second
dose of MMR vaccine should be administered (see Documentation of Immunity).
IG or MIG administered simultaneously with further attenuated measles vaccines
(i.e., vaccines containing the Schwarz or Moraten virus strains) may have impaired
the immune response to vaccination. Persons who received measles vaccine of un-
known type or further attenuated measles vaccine accompanied by IG or MIG should
be considered unvaccinated and should be administered two doses of MMR vaccine.
Persons vaccinated with other previously licensed live rubella vaccines that were not
administered with IG or MIG (i.e., HPV-77 or Cendehill vaccines) need not be revacci-
nated against rubella.
Previous vaccination with inactivated measles vaccine or measles vaccine of un-
known type. Inactivated (killed) measles vaccine was available in the United States
only from 1963 to 1967 but was available through the early 1970s in some other coun-
tries. It was frequently administered as a series of two or three injections. Because
persons who received inactivated vaccine are at risk for developing severe atypical
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measles syndrome when exposed to the natural virus, they should receive two doses
of MMR or other live measles vaccine, separated by at least 28 days (147 ). Persons
who received inactivated vaccine followed within 3 months by live virus vaccine
should also be revaccinated with two more doses of MMR or other live measles vac-
cine. Revaccination is particularly important when the risk for exposure to natural
measles virus is increased (e.g., during international travel).
Persons vaccinated during 1963–1967 with vaccine of unknown type may have re-
ceived inactivated vaccine and also should be revaccinated. Persons who received a
vaccine of unknown type after 1967 need not be revaccinated unless the original vac-
cination occurred before the first birthday or was accompanied by IG or MIG.
However, such persons should receive a second dose before entering college, begin-
ning work in a health-care facility, or undertaking international travel.
Some recipients of inactivated measles vaccine who were later revaccinated with
live measles vaccine have had adverse reactions to the live vaccine; the percentage
who reported adverse reactions ranges from 4% to 55% (148 ). In most cases, these
reactions were mild (e.g., local swelling and erythema, low-grade fever lasting 1–
2 days), but rarely more severe reactions (e.g., prolonged high fevers, extensive local
reactions) have been reported. However, natural measles infection is more likely to
cause serious illness among recipients of inactivated measles vaccine than is live
measles virus vaccine.
Previous vaccination with inactivated mumps vaccine or mumps vaccine of unknown
type. A killed mumps virus vaccine was licensed for use in the United States from
1950 through 1978. Although this vaccine induced antibody, the immunity was tran-
sient. The number of doses of killed mumps vaccine administered between licensure
of live attenuated mumps vaccine in 1967 until the killed vaccine was withdrawn in
1978 is unknown but appears to have been limited.
Revaccination with MMR should be considered for certain persons vaccinated be-
fore 1979 with either killed mumps vaccine or mumps vaccine of unknown type who
are at high risk for mumps infection (e.g., persons who work in health-care facilities
during a mumps outbreak). No evidence exists that persons who have had mumps
disease or who have previously received mumps vaccine (killed or live) are at in-
creased risk for local or systemic reactions upon receiving MMR or live mumps
vaccine.
ADVERSE EVENTS AFTER MMR VACCINATION
Adverse events associated with administration of MMR vaccine range from local
pain, induration, and edema to rare systemic reactions such as anaphylaxis. Side ef-
fects tend to occur among vaccine recipients who are nonimmune and therefore are
very rare after revaccination (see Revaccination). Expert committees at the Institute of
Medicine (IOM) recently reviewed all evidence concerning the causal relationship be-
tween MMR vaccination and various adverse events (149,150 ). The IOM determined
that evidence establishes a causal relation between MMR vaccination and anaphy-
laxis, thrombocytopenia, febrile seizures, and acute arthritis. Although vasculitis, otitis
media, conjunctivitis, optic neuritis, ocular palsies, Guillain-Barré syndrome, and
ataxia have been reported after administration of MMR or its component vaccines and
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are listed in the manufacturer’s package insert, no causal relationship has been estab-
lished between these events and MMR vaccination.
Evidence does not support a causal association of administration of measles-
containing vaccine with risk for Crohn disease, a hypothesis proposed by some re-
searchers in the United Kingdom and Sweden (151–156 ). Other researchers have
been unable to replicate the laboratory findings that were reported to support this
hypothesized association (157,158 ). Concerns also have been raised about the meth-
ods used in the epidemiologic studies that suggested an association between Crohn
disease and measles vaccination (159–163 ). Other data do not support an association
between measles vaccination and risk for Crohn disease or other inflammatory bowel
disease (164,165 ).
Infection with mumps virus may trigger the onset of diabetes mellitus in some per-
sons. However, no association has been established between vaccination with MMR
or other mumps virus vaccine and pancreatic damage or subsequent development of
diabetes mellitus (150 ).
Fever, Rash, Lymphadenopathy, or Parotitis
Measles, rubella, and mumps vaccines may cause fever after vaccination; the mea-
sles component of MMR vaccine is most often associated with this adverse event.
Approximately 5% of children develop a temperature of ≥103 F (≥39.4 C) after MMR
vaccination. Such febrile reactions usually occur 7–12 days after vaccination and gen-
erally last 1–2 days (166 ). Most persons with fever are otherwise asymptomatic.
Measles- and rubella-containing vaccines (including MMR) can cause transient
rashes, which usually appear 7–10 days after vaccination, in approximately 5% of vac-
cinated persons. Transient lymphadenopathy sometimes occurs following admin-
istration of MMR or other rubella-containing vaccine, and parotitis has been reported
rarely following administration of MMR or other mumps-containing vaccine.
Allergic Reactions
Hypersensitivity reactions, usually consisting of urticaria or a wheal and flare at the
injection site, occur rarely after administration of MMR or any of its component vac-
cines. Immediate anaphylactic reactions to these vaccines are very rare. More than
70 million doses of MMR vaccine have been distributed in the United States since the
Vaccine Adverse Events Reporting System (VAERS) was implemented in 1990. The
reported rate of possible anaphylaxis after vaccination with measles-containing vac-
cine is <1 case per 1 million doses distributed (CDC, unpublished data). Allergic
reactions including rash, pruritus, and purpura have been temporally associated with
mumps vaccination but are uncommon, usually mild, and of brief duration.
Thrombocytopenia
Surveillance of adverse reactions in the United States and other countries indicates
that MMR vaccine can, in rare instances, cause clinically apparent thrombocytopenia
within 2 months after vaccination. In prospective studies, the reported frequency
of clinically apparent thrombocytopenia after MMR vaccination ranged from 1 case
per 30,000 vaccinated children in Finland and Great Britain (167,168 ) to 1 case per
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40,000 in Sweden (169 ), with a temporal clustering of cases occurring 2–3 weeks after
vaccination. Based on passive surveillance, the reported frequency of thrombocy-
topenia was approximately 1 case per 100,000 vaccine doses distributed in Canada
(170 ) and France (171 ), and approximately 1 case per 1 million doses distributed in
the United States (172 ). The clinical course of these cases was usually transient and
benign, although hemorrhage occurred rarely (172 ). The risk for thrombocytopenia
during rubella or measles infection is much greater than the risk after vaccination
(173 ). Based on case reports, the risk for MMR-associated thrombocytopenia may be
increased for persons who have previously had immune thrombocytopenic purpura,
particularly for those who had thrombocytopenic purpura after an earlier dose of
MMR vaccine (150,174,175 ).
Neurological Events
Adverse neurological events after administration of MMR vaccine are rare. Reports
of nervous system illness following MMR vaccination do not necessarily denote
an etiologic relationship between the illness and the vaccine. Although several cases
of sensorineural deafness have been reported after administration of MMR vaccine,
evidence from these case reports (e.g., timing of onset and other features) is inade-
quate to accept or reject a causal relation between MMR vaccination and sensor-
ineural deafness.
Aseptic Meningitis
Aseptic meningitis has been clearly associated with administration of the Urabe
strain mumps vaccine virus but not with the Jeryl Lynn strain, which is the only
mumps vaccine used in the United States (176–178 ). Sentinel surveillance laborato-
ries in the United Kingdom identified thirteen aseptic meningitis cases (91 cases per
1 million doses distributed) that occurred after administration of the Urabe strain vac-
cine during 1988–1992 (168 ). Since the United Kingdom switched to Jeryl Lynn strain
vaccine in 1992, no mumps vaccine-associated aseptic meningitis cases have been
reported by the surveillance laboratories (178 ).
Subacute Sclerosing Panencephalitis (SSPE)
Measles vaccination substantially reduces the occurrence of SSPE as evidenced by
the near elimination of SSPE cases after widespread measles vaccination. SSPE has
been reported rarely among children who had no history of natural measles infection,
but who had received measles vaccine. Evidence indicates that at least some of these
children had unrecognized measles infection before they were vaccinated and that the
SSPE was directly related to the natural measles infection. The administration of live
measles vaccine does not increase the risk for SSPE, even among persons who have
previously had measles disease or received live measles vaccine (150,179 ).
Encephalopathy/Encephalitis
Encephalitis with resultant residual permanent central nervous system (CNS) im-
pairment (encephalopathy) develops in approximately 1 per 1,000 persons infected
with measles virus. Whether attenuated live viral measles vaccine can also produce
such a syndrome has been a concern since the earliest days of measles vaccine use.
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In 1994, the IOM noted that most data were from case reports, case series, or uncon-
trolled observational studies, and concluded that the evidence was inadequate to
accept or reject a causal relation (150 ).
The British National Childhood Encephalopathy Study (NCES) identified a fourfold
elevation in risk for encephalopathy or convulsions among children who received
measles vaccine during 1976–1979, compared with the risk for these conditions
among unvaccinated children (180). Among previously normal children, the attribut-
able risk for acute encephalopathy or convulsions was 1 case per 87,000 vaccinations.
Findings of a subsequent 10-year follow-up study of persons diagnosed with convul-
sions or acute encephalopathy in the NCES indicated little difference in risk for
persisting neurological abnormality among those who had received measles vaccine
compared with those who had not (E. Miller, personal communication).
Although cases of encephalopathy have been reported after administration of mea-
sles-containing vaccine (181 ), lack of a unique clinical syndrome or specific laboratory
test has hampered causality assessment. However, four independent passive surveil-
lance systems in the United States (i.e., CDC measles surveillance from 1963 to 1971,
the Monitoring System for Adverse Events Following Immunizations [MSAEFI] from
1979 to 1990, the Vaccine Adverse Event Reporting System [VAERS] from 1991 to
1996, and the Vaccine Injury Compensation Program [VICP]) have reported cases of
encephalopathy in which a similar timing of reported events following vaccine ad-
ministration is apparent. In all four case series, onset of encephalopathies follows a
non-random distribution with onset approximately 10 days after vaccination, a timing
consistent with onset of encephalopathy after infection with wild measles virus (182 ).
Although this pattern may be in part attributable to consistent biases of these passive
surveillance systems, it is also consistent with a causal relationship between measles
vaccine and encephalopathies (183 ). During the period these four systems have col-
lected data, 166 cases of encephalopathy occurring 6–15 days after vaccination have
been identified and an estimated 313 million doses of measles-containing vaccines
have been distributed (i.e., approximately 1 case per 2 million doses distributed).
Thus, encephalopathy occurs much less frequently after administration of measles
vaccine than after measles infection.
Febrile Seizures and Personal and Family History of Convulsions
MMR vaccination, like other causes of fever, may cause febrile seizures. The risk for
such seizures is approximately 1 case per 3,000 doses of MMR vaccine administered
(168 ). Studies have not established an association between MMR vaccination and re-
sidual seizure disorders (150 ). Although children with personal or family histories of
seizures are at increased risk for idiopathic epilepsy, febrile seizures after vaccinations
do not increase the probability that epilepsy or other neurologic disorders will sub-
sequently develop in these children. Most convulsions that occur after measles
vaccination are simple febrile seizures, which affect children who do not have other
known risk factors for seizure disorders.
Antipyretics may prevent febrile seizures after MMR vaccination if administered
before the onset of fever and continued for 5–7 days. However, antipyretics are diffi-
cult to use for this purpose because the onset of fever is often sudden and occurs
unpredictably. Seizures can occur early in the course of fever. Parents should be vigi-
lant for fever that occurs after vaccination and should be counseled regarding its
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appropriate treatment. Use of aspirin during some illnesses in childhood is associated
with the occurrence of Reye syndrome. Therefore, aspirin generally should not be
used to prevent or control fever among children and adolescents.
The 5%–7% of children who have either a personal history of convulsions or a par-
ent or sibling with history of convulsions may be at increased risk for febrile con-
vulsions after MMR vaccination (184 ). The precise risk has not been measured, but
appears to be minimal. On the other hand, febrile seizures occur commonly among
children in whom measles disease develops, and the risk for acquiring measles is sub-
stantial. Therefore, the benefits of administering MMR vaccine to children with a
personal or family history of convulsions substantially outweigh the risks and these
children should be vaccinated following the recommendations for children who have
no contraindications.
Children who are being treated with anticonvulsants should continue to take them
after measles vaccination. Because protective levels of most currently available anti-
convulsant drugs (e.g., phenobarbital) are not achieved for some time after therapy is
initiated, prophylactic use of these drugs is not feasible.
The parents of children who have either a personal or family history of seizures
should be advised of the benefits of vaccination and the minimal increased risk for
seizures, which generally occur 5–14 days after measles vaccination.
Guillain-Barré Syndrome (GBS)
Cases of GBS occurring after administration of MMR or its component vaccines
have been reported, but the IOM judged the evidence insufficient to accept or reject a
causal relationship (150 ). Recent studies provide evidence against this potential asso-
ciation (185,186 ). After recent mass vaccination campaigns that involved approx-
imately eight million doses of measles-rubella vaccine in the United Kingdom and
>70 million doses of measles vaccine in Latin America, evaluations of GBS incidence
demonstrated no increases over background rates.
Arthralgia, Arthritis, and Persistent or Recurrent Arthropathy
Joint symptoms are associated with the rubella component of MMR. Among sus-
ceptible persons who receive rubella vaccine, arthralgia and transient arthritis occur
more frequently among adults than among children and more frequently among post-
pubertal females than among males. Acute arthralgia or arthritis are rare among
children who receive RA 27/3 vaccine (187 ). By contrast, arthralgia develops among
approximately 25% of susceptible postpubertal females after RA 27/3 vaccination and
approximately 10% have acute arthritis-like signs and symptoms (188,189 ). Although
rare reports of transient peripheral neuritic complaints have occurred, insufficient evi-
dence exists to indicate a causal relation between RA 27/3 vaccine and peripheral
neuropathies (149,190 ). When acute joint symptoms occur, or when pain and/or
paresthesias not associated with joints occur, they generally begin 1–3 weeks after
vaccination, persist for 1 day to 3 weeks, and rarely recur. Adults who experienced
acute joint symptoms after rubella vaccination usually have not had to disrupt work
activities (189,190,191 ).
A 1991 report by the IOM stated that although some data were consistent with
a causal relation between RA27/3 rubella vaccine and chronic arthritis among adult
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women, the evidence was limited in scope and confined to reports from a single insti-
tution (149 ). Several more recently published studies have found no evidence of
increased risk for new onset of chronic arthropathies among women vaccinated with
RA 27/3 vaccine (192–194 ). In addition, data from a recent prospective, randomized,
placebo-controlled trial by the same group that initially reported chronic arthropathy
after rubella vaccination demonstrated only a small excess risk for persistent joint
symptoms among persons who received rubella vaccine (relative risk [RR] = 1.58; 95%
confidence interval = 1.01–2.45) (195 ). Neither the duration of arthropathy nor timing
of onset was reported. The occurrence of arthropathy described as moderate or se-
vere did not differ between vaccine and placebo recipients and was rare in both
groups.
Interference with Tuberculin Skin Tests
Tuberculin testing is not a prerequisite for vaccination with MMR or any of its com-
ponent vaccines. MMR vaccine may interfere with the response to a tuberculin test
(196–198 ). Therefore, tuberculin testing, if otherwise indicated, can be done either on
the same day MMR vaccine is administered or 4–6 weeks later. 
Revaccination
No evidence indicates that administration of live measles, mumps, or rubella vac-
cine increases the risk for adverse reactions among persons who are already immune
to these diseases as a result of previous vaccination or natural disease. Data indicate
that only persons who are not immune when vaccinated tend to have postvaccination
side effects similar to the disease symptoms (139 ). No evidence exists that persons
who have previously received killed mumps vaccine or had mumps disease are at
increased risk for local or systemic reactions from receiving live mumps vaccine.
Some recipients of inactivated measles vaccine who were later revaccinated with live
measles vaccines have had adverse reactions to the live vaccine (see Revaccination of
Persons Vaccinated According to Earlier Recommendations).
REPORTING ADVERSE EVENTS
Reporting of serious adverse events that occur after administration of MMR or its
component vaccines helps identify adverse events that may be caused by these vac-
cines. The National Childhood Vaccine Injury Act of 1986 requires health-care
providers to report serious adverse events that occur after vaccination with MMR and
its component vaccines to the Vaccine Adverse Events Reporting System (VAERS).
Persons other than health-care workers can also report adverse events to VAERS.
Events that must be reported after MMR vaccination are listed in the reportable events
table within the Act and include anaphylaxis or anaphylactic shock occurring within
7 days of vaccination, encephalopathy (or encephalitis) occurring within 7 days of vac-
cination, and any events described in the manufacturer’s package insert as
contraindications to additional doses of vaccine (199 ). Other adverse events occur-
ring after administration of a vaccine, especially events that are serious or unusual,
also should be reported to VAERS, regardless of the provider’s opinion of the causality
of the association. VAERS reporting forms and information are available 24 hours a
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day by calling 1-800-822-7967 or via the World Wide Web at http:\\www.cdc.gov/nip/
vaers.htm.
VACCINE INJURY COMPENSATION
The National Vaccine Injury Compensation Program, established by the National
Childhood Vaccine Injury Act of 1986, is a system under which compensation may be
paid on behalf of a person thought to have been injured or to have died as a result of
receiving a vaccine covered by the program. The program is intended as an alternative
to civil litigation under the traditional tort system because negligence need not be
proven.
The Act establishes a) a Vaccine Injury Compensation Table that lists the vaccines
covered by the program; b) the injuries, disabilities, and conditions (including death)
for which compensation may be paid without proof of causation; and c) the period
after vaccination during which the first symptom or substantial aggravation of the
injury must appear. Modifications to the Vaccine Injury Table became effective March
24, 1997 (199 ). Persons may be compensated for an injury listed in the established
table or one that can be demonstrated to result from administration of a listed vaccine.
Additional information about the program is available.*
PRECAUTIONS AND CONTRAINDICATIONS
Pregnancy
MMR and its component vaccines should not be administered to women known to
be pregnant. Because a risk to the fetus from administration of these live virus vac-
cines cannot be excluded for theoretical reasons, women should be counseled to
avoid becoming pregnant for 30 days after vaccination with measles or mumps vac-
cines and for 3 months after administration of MMR or other rubella-containing
vaccines. Routine precautions for vaccinating postpubertal women with MMR should
be followed in all vaccination programs (see Routine Vaccination—Women of Child-
bearing Age). If a pregnant woman is vaccinated or if she becomes pregnant within
3 months after vaccination, she should be counseled about the theoretical basis of
concern for the fetus, but MMR vaccination during pregnancy should not ordinarily be
a reason to consider termination of pregnancy. Rubella-susceptible women who are
not vaccinated because they state they are or may be pregnant should be counseled
about the potential risk for CRS and the importance of being vaccinated as soon as
they are no longer pregnant.
Because birth defects are noted in 3%–5% of all births, confusion about the etiology
of birth defects may result if vaccine is administered during pregnancy. Although of
theoretical concern, no cases of congenital rubella syndrome or abnormalities attrib-
utable to infection with measles, rubella, or mumps vaccine virus infection have been
*National Vaccine Injury Compensation Program, Health Resources and Services Administra-
tion, Parklawn Building, Room 8-05, 5600 Fishers Lane, Rockville MD 20857, Telephone: (800)
338-2382 (24-hour recording).  Internet Home Page: “http://www.hrsa.dhhs.gov/
bhpr/vicp/new.htm.”
Persons wishing to file a claim for vaccine injury should write to: U.S. Court of Federal Claims,
717 Madison Place, NW, Washington DC 20005. Telephone: (202) 219-9657.
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observed among infants born to susceptible mothers who received any of these vac-
cines during pregnancy. From January 1971 through April 1989, CDC followed to term
321 known rubella-susceptible pregnant women who had been vaccinated with live
rubella vaccine within 3 months before or 3 months after conception. Ninety-four
women received HPV-77 or Cendehill vaccines, one received vaccine of unknown
strain, and 226 received RA 27/3 vaccine (the only rubella vaccine presently used in the
United States). None of the 324 infants born to these mothers had malformations
compatible with congenital rubella infection. This total included five infants who had
serologic evidence of subclinical infection; three of the infants were exposed to HPV-
77 or Cendehill vaccine and two were exposed to RA 27/3 vaccine. Based on these
data, the estimated risk for serious malformations attributable to RA 27/3 rubella vac-
cine ranges from zero to 1.6%. If the infants exposed to other rubella vaccines are
included, the estimated risk is zero to 1.2%, substantially less than the ≥20% risk for
CRS associated with maternal infection during the first trimester of pregnancy (200 ).
Moreover, the observed risk for CRS with both the HPV-77 or Cendehill and RA 27/3
strains of vaccine is zero.
Rubella vaccine virus has been isolated from the aborted fetus of one (3%) of 35
rubella-susceptible women who received RA 27/3 strain vaccine during pregnancy. In
contrast, vaccine virus was isolated from the fetuses of 17 (20%) of 85 women to
whom HPV-77 or Cendehill vaccines were administered (201). This finding provides
additional evidence that the RA 27/3 vaccine poses no greater risk for teratogenicity
than did the HPV-77 or Cendehill vaccines.
Breast feeding is not a contraindication to vaccination. Although a woman can ex-
crete rubella vaccine virus in breast milk and transmit the virus to her infant, the
infection remains asymptomatic (202–205 ). Otherwise, persons who receive MMR or
its component vaccines do not transmit measles, rubella, or mumps vaccine viruses
(206,207 ). Thus, MMR vaccine can be administered safely to susceptible children or
other persons with household contacts who are pregnant to help protect these preg-
nant women from exposure to wild rubella virus.
All suspected cases of CRS, whether presumed to be due to wild-virus or vaccine-
virus infection, should be reported to state and local health departments. Suspected or
confirmed cases of CRS can also be reported to the VAERS (see Reporting Adverse
Events).
Severe Illness
Because of the importance of protecting susceptible children against measles,
mumps, and rubella, medical personnel should use every opportunity to vaccinate
susceptible persons. The decision to vaccinate or postpone vaccination of a person
who currently has or recently has had an acute febrile illness depends largely on
the cause of the illness and the severity of symptoms. Minor illnesses, with or without
fever (e.g., diarrhea, upper respiratory infection, otitis media) are not contraindica-
tions for vaccination and vaccination should not be postponed because of them. Data
indicate that seroconversion rates for each component of MMR vaccine among per-
sons with mild febrile illness are similar to those among healthy persons (208,209 ).
Similarly, performing routine physical examinations or measuring temperatures
are not prerequisites for vaccinating persons who appear to be in good health. In
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childhood vaccination programs, appropriate procedures include a) asking the parent
or guardian if the child is ill, b) postponing vaccination of children who have moderate
or severe febrile illnesses, and c) vaccinating children who do not have other contra-
indications. 
Vaccination of persons with moderate or severe febrile illnesses should generally
be deferred until they have recovered from the acute phase of their illness. This wait
avoids superimposing adverse effects of vaccination on the underlying illness or mis-
takenly attributing a manifestation of the underlying illness to the vaccine. Data are
generally not available regarding the safety and immunogenicity of MMR vaccine
among persons with moderate or severe febrile illness.
Persons under treatment for tuberculosis have not experienced exacerbations
of the disease when vaccinated with MMR. Although no studies have been reported
concerning the effect of MMR vaccine on persons with untreated tuberculosis, a theo-
retical basis exists for concern that measles vaccine might exacerbate tuberculosis.
Consequently, before administering MMR to persons with untreated active tuberculo-
sis, initiating antituberculous therapy is advisable. Tuberculin testing is not a pre-
requisite for routine vaccination with MMR or other measles-containing vaccines.
Allergies
Among persons who are allergic to eggs, the risk for serious allergic reactions such
as anaphylaxis following administration of measles- or mumps-containing vaccines is
extremely low and skin-testing with vaccine is not predictive of allergic reaction to
vaccination (210–212 ). Therefore, skin testing is not required before administering
MMR (or other measles- and mumps-containing vaccines) to persons who are allergic
to eggs. Similarly, the administration of gradually increasing doses of vaccine is not
required. In the past, persons with a history of anaphylactic reactions (i.e., hives, swel-
ling of the mouth or throat, difficulty breathing, hypotension, and shock) following
egg ingestion were considered to be at increased risk for serious reactions after ad-
ministration of measles- or mumps-containing vaccines, which are produced in chick
embryo fibroblasts. Although protocols have been developed for skin testing and vac-
cination of persons who experience anaphylactic reactions to egg ingestion, data
indicate that most anaphylactic reactions to measles- and mumps-containing vaccines
are not associated with hypersensitivity to egg antigens but to other components of
the vaccines (213–217 ).
The literature contains several case reports of persons with an anaphylactic sensi-
tivity to gelatin who had anaphylactic reactions after receiving MMR vaccine
(218–220 ). MMR and its component vaccines contain hydrolyzed gelatin as a stabi-
lizer. Therefore, extreme caution should be exercised when administering MMR or its
component vaccines to persons who have a history of an anaphylactic reaction to
gelatin or gelatin-containing products. Before administering MMR or its component
vaccines to such persons, skin testing for sensitivity to gelatin can be considered.
However, no specific protocols for this purpose have been published.
Because MMR and its component vaccines contain trace amounts of neomycin
(25 µg), persons who have experienced anaphylactic reactions to topically or systemi-
cally administered neomycin should not receive these vaccines. However, neomycin
allergy is most often manifested as a delayed or cell-mediated immune response (i.e.,
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a contact dermatitis), rather than anaphylaxis. In persons who have such a sensitivity,
the adverse reaction to the neomycin in the vaccine is an erythematous, pruritic nod-
ule or papule appearing 48–96 hours after vaccination. A history of contact dermatitis
to neomycin is not a contraindication to receiving MMR vaccine. MMR vaccine does
not contain penicillin and therefore a history of penicillin allergy is not a contraindica-
tion to MMR vaccination.
Although anaphylaxis after vaccination is extremely rare and no anaphylaxis
deaths associated with administration of MMR vaccine have been reported, this
adverse event can be life threatening (150 ). Epinephrine should be available for
immediate use at any site where vaccines are administered in case symptoms of ana-
phylaxis occur.
Thrombocytopenia
Children who have a history of thrombocytopenia or thrombocytopenic purpura
may be at increased risk for developing clinically significant thrombocytopenia after
MMR vaccination (172,175 ). Although thrombocytopenia can be life threatening, no
deaths have been reported as a direct consequence of vaccine-induced thrombocy-
topenia. The decision to vaccinate with MMR should depend on the benefits of
immunity to measles, mumps, and rubella and the risks for recurrence or exacerbation
of thrombocytopenia after vaccination or during natural infection with measles or ru-
bella. The benefits of primary immunization are usually greater than the potential
risks, and administration of MMR vaccine is justified, particularly with regard to the
even greater risk for thrombocytopenia after measles or rubella disease. However,
avoiding a subsequent dose of MMR vaccine may be prudent if an episode of throm-
bocytopenia occurred within approximately 6 weeks after a previous dose of the
vaccine. Serologic evidence of measles immunity among such persons may be
sought in lieu of MMR vaccination.
Recent Administration of Immune Globulins
Recent evidence indicates that high doses of immune globulins can inhibit the im-
mune response to measles and rubella vaccine for 3 or more months (221, 222 ). The
duration of this interference with the immune response depends on the dose of im-
mune globulin administered. The effect of immune globulin preparations on the
response to mumps vaccine is unknown. Blood (e.g., whole blood, packed red blood
cells, and plasma) and other antibody-containing blood products (e.g., IG, specific
immune globulins, and IGIV) can reduce the immune response to MMR or its compo-
nent vaccines. Therefore, these vaccines should be administered to persons who have
received an immune globulin preparation only after the recommended intervals
have elapsed (Table 3) (80 ). However, postpartum administration of MMR or rubella
vaccine to women who are susceptible to rubella should not be delayed because anti-
Rho(D) immune globulin (human) or any other blood product was received during the
last trimester of pregnancy or at delivery. Such rubella-susceptible women should be
vaccinated immediately after delivery and tested at least 3 months later to ensure that
they are immune to rubella and measles.
Immune globulin preparations generally should not be administered simultane-
ously with MMR or its component vaccines. If administration of an immune globulin
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preparation becomes necessary because of imminent exposure to disease, MMR or its
component vaccines can be administered simultaneously with the IG preparation,
although vaccine-induced immunity may be compromised. Usually, vaccine virus rep-
lication and stimulation of immunity will occur 1–2 weeks after vaccination. Thus, if
the interval between administration of any of these vaccines and administration of an
IG preparation is <14 days, vaccination should be repeated after the recommended
interval (Table 3), unless serologic testing indicates that the vaccinated person’s im-
mune system has produced antibodies to each vaccine component (i.e., measles,
rubella, and mumps). The vaccine should be administered at an anatomic site remote
from that chosen for the IG injection.
Altered Immunocompetence
Enhanced replication of vaccine viruses may occur in persons who have immune
deficiency diseases and in other persons who are immunosuppressed. Severe immu-
nosuppression may be caused by many disease conditions (e.g., congenital
immunodeficiency, HIV infection, hematologic or generalized malignancy) and by
therapy with immunosuppressive agents, including large doses of corticosteroids. For
some of these conditions, all affected persons are severely immunocompromised. For
other conditions (e.g., HIV infection), the degree to which the immune system is com-
promised depends on the severity of the condition, which in turn depends on the
disease or treatment stage. Ultimately, the patient’s physician must assume responsi-
bility for determining whether the patient is severely immunocompromised based on
clinical and laboratory assessment.
Case reports have linked vaccine-associated measles infection to the deaths of
some severely immunocompromised persons (150,223 ). Therefore, MMR vaccine
should not be administered to severely immunocompromised persons. To reduce
the risk for measles, rubella, and mumps exposure of immunocompromised patients,
their susceptible close contacts should be vaccinated with MMR. No case reports exist
linking MMR or mumps- or rubella-containing vaccines with clinically significant infec-
tion caused by mumps or rubella vaccine virus among immunocompromised vaccine
recipients.
HIV-Infected Persons
Among asymptomatic and symptomatic HIV-infected patients who are not severely
immunosuppressed, MMR vaccination has been associated with variable antibody re-
sponses but not with severe or unusual adverse events. Asymptomatic persons do not
need to be evaluated and tested for HIV infection before MMR and other measles-
containing vaccines are administered. MMR vaccine is recommended for all asympto-
matic HIV-infected persons who are not severely immunosuppressed and who lack
evidence of measles immunity. MMR vaccination of symptomatic HIV-infected
persons should be considered if they a) do not have evidence of severe immuno-
suppression and b) lack evidence of measles immunity. MMR and other measles-con-
taining vaccines are not recommended for HIV-infected persons with evidence of
severe immunosuppression (see Special Considerations for Vaccination—Persons In-
fected with Human Immunodeficiency Virus [HIV]) (Table 2).
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Steroids
Systemically absorbed corticosteroids can suppress the immune system of an oth-
erwise healthy person. However, neither the minimum dose nor the duration of
therapy sufficient to cause immune suppression are well defined. Most experts agree
that steroid therapy usually does not contraindicate administration of live virus vac-
cines such as MMR and its component vaccines when therapy is: a) short term (i.e.,
<14 days) low-to-moderate dose; b) low-to-moderate dose administered daily or on
alternate days; c) long term alternate day treatment with short-acting preparations;
d) physiologic maintenance doses (replacement therapy); or e) administered topically
(skin or eyes), by aerosol, or by intra-articular, bursal, or tendon injection. Although
the immunosuppressive effects of steroid treatment vary, many clinicians consider a
steroid dose that is equivalent to or greater than a prednisone dose of 2 mg/kg of body
weight per day or a total of 20 mg per day sufficiently immunosuppressive to raise
concern about the safety of administration of live virus vaccines. Persons who have
received systemic corticosteroids in these or greater doses daily or on alternate days
for an interval of ≥14 days should avoid vaccination with MMR and its component
vaccines for at least 1 month after cessation of steroid therapy. Persons who have
received prolonged or extensive topical, aerosol, or other local corticosteroid therapy
that causes clinical or laboratory evidence of systemic immunosuppression should
also avoid vaccination with MMR for at least 1 month after cessation of therapy. Per-
sons who receive doses of systemic corticosteroids equivalent to a prednisone dose
of ≥2 mg/kg of body weight or ≥20 mg total daily or on alternate days during an inter-
val of <14 days generally can receive MMR or its component vaccines immediately
after cessation of treatment, although some experts prefer waiting until 2 weeks after
completion of therapy. MMR or its component vaccines generally should not be
administered to persons who have a disease that, in itself, suppresses the immune re-
sponse and who are receiving either systemic or locally administered corticosteroids.
Leukemia
Persons with leukemia in remission who were not immune to measles, rubella, or
mumps when diagnosed with leukemia may receive MMR or its component vaccines.
At least 3 months should elapse after termination of chemotherapy before administra-
tion of the first dose of MMR vaccine. 
Management of Patients with Contraindications to Measles
Vaccine
If immediate protection against measles is required for persons with contraindica-
tions to measles vaccination, 0.25 mL/kg (0.11 mL/lb) of body weight (maximum
dose = 15 mL) of IG should be administered as soon as possible after known exposure
(See Use of Vaccine and Immune Globulin Among Persons Exposed to Measles,
Rubella, or Mumps). Exposed symptomatic HIV-infected and other immunocom-
promised persons should receive IG regardless of their previous vaccination status.
Because IG in usual doses may not be effective for immunocompromised persons, the
recommended dose is 0.5 mL/kg of body weight if IG is administered intramuscularly
(maximum dose = 15 mL). This corresponds to a dose of IgG protein of approximately
82.5 mg/kg (maximum dose = 2,475 mg). Intramuscular IG may not be needed if a
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patient is receiving at least 100–400 mg/kg IGIV at regular intervals and exposure oc-
curs within 3 weeks after administration of the last dose of IGIV. Because the amounts
of protein administered are similar, high-dose IGIV may be as effective as intramuscu-
lar IG. However, no data are available concerning the effectiveness of IGIV in
preventing measles.
The effectiveness of IG or IGIV for preventing mumps or rubella is unknown. These
products should not be used for prophylaxis among immunocompromised persons
exposed to these diseases.
SURVEILLANCE AND OUTBREAK CONTROL
Surveillance for vaccine preventable diseases has four primary purposes: a) to pro-
vide important data on program progress and long term trends, b) to provide the basis
for changes in disease prevention strategies, c) to help define groups in greatest need
of vaccination, and d) to evaluate vaccine safety and effectiveness (e.g., protective
efficacy, duration of vaccine-induced immunity, and occurrence of adverse effects). As
the incidence of measles, rubella, and mumps declines in the United States, enhanced
surveillance becomes increasingly important.
Any person aware of a suspected or known cases of measles, rubella, congenital
rubella syndrome, or mumps should report the case to the local or state health depart-
ment. The designated public health authorities should investigate the case imm-
ediately. The purpose of the investigation is to classify the case, identify the charac-
teristics of the case and the source of exposure, and prevent further spread.
Cases of measles, rubella, and congenital rubella syndrome are reportable in all
states, and mumps is reportable in most states. Data from measles, rubella, congeni-
tal rubella syndrome, and mumps cases are routinely reported by state and local
health departments to CDC and published weekly in the Morbidity and Mortality
Weekly Report.
Measles Case Investigation and Outbreak Control
Case Definition
A suspected measles case is defined as any febrile illness accompanied by rash.
Suspected and known cases of measles should be reported immediately to the local
or state health department. The designated public health authorities should quickly
initiate an investigation of the reported case. Rapid case reporting and investigation
can help limit further transmission.
A clinical case of measles is defined as an illness characterized by
• a generalized rash lasting ≥3 days, and
• a temperature of ≥38.3 C (≥101 F), and
• cough, coryza, or conjunctivitis. 
A probable case of measles
• meets the clinical case definition for measles, and
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• is not epidemiologically linked to a confirmed case, and
• has not been serologically or virologically tested or has noncontributory sero-
logic or virologic results. 
A confirmed case of measles
• meets the laboratory criteria for measles or
• meets the clinical case definition and is epidemiologically linked to a confirmed
case.
Confirmed measles cases are routinely reported to CDC by state health departments.
Laboratory Diagnosis
The laboratory criteria for measles diagnosis are: 
• a positive serologic test for measles IgM antibody, or
• a significant rise in measles antibody level by any standard serologic assay, or 
• isolation of measles virus from a clinical specimen. 
A laboratory-confirmed case need not meet the clinical case definition. Serologic
confirmation should be attempted for every suspected case of measles and is particu-
larly important for any case that cannot be epidemiologically linked through a chain of
transmission to a confirmed case. However, reporting of suspected or probable cases,
investigation of cases, and the implementation of control activities should not be de-
layed pending laboratory results.
Blood for serologic testing should be collected during the first clinical encounter
with a person who has suspected or probable measles. The serum should be tested
for measles IgM antibody as soon as possible using an assay that is both sensitive and
specific (e.g., direct-capture IgM EIA method). Correct interpretation of serologic data
depends on the timing of specimen collection in relation to rash onset and on the
characteristics of the antibody assay used. This timing is especially important for in-
terpreting negative results because IgM antibody may not be detectable with some
less sensitive assays until at least 72 hours after rash onset. Measles IgM may be de-
tectable at the time of rash onset, peaks approximately 10 days after rash onset, and
is usually undetectable 30–60 days after rash onset. In general, if measles IgM is not
detected in a serum specimen obtained in the first 72 hours after rash onset from a
person whose illness meets the clinical case definition for measles, another specimen
should be obtained at least 72 hours after rash onset and tested for measles IgM anti-
body. Measles IgM is detectable for at least 1 month after rash onset. Persons with
febrile rash illnesses who are seronegative for measles should be tested for rubella.
As measles becomes rare in the United States, the likelihood of obtaining false
positive serologic results from measles IgM antibody testing increases. False positive
results have been obtained by using a commercially available ELISA assay for mea-
sles IgM in persons with parvovirus infection (fifth disease) (224 ). Confirmatory
testing by using an assay that is both sensitive and specific (e.g., direct-capture IgM
EIA method) should be considered when IgM is detected in a patient with suspected
Vol. 47 / No. RR-8 MMWR 39
measles who has no identified source of infection and no epidemiologic linkage to
another confirmed case. The Measles Virus Laboratory of CDC’s National Center for
Infectious Diseases has provided training to all state public health laboratories to per-
form such testing.
Serologic diagnosis of measles can also be confirmed by a significant rise in anti-
body titer between acute- and convalescent-phase serum specimens. Typically, the
acute-phase serum specimen is obtained within 1–3 days after rash onset and the con-
valescent-phase specimen is obtained approximately 2–4 weeks later. This method
has been largely supplanted by IgM assays which can be done on a single serum
specimen obtained soon after rash onset.
Asymptomatic measles reinfection can occur among persons who have previously
developed antibodies from vaccination or from natural disease. Symptomatic reinfec-
tions accompanied by rises in measles antibody titers are rare, and those resulting in
detectable measles IgM antibody occur even more rarely.
Molecular characterization of measles virus isolates has become an important tool
for defining the epidemiologic features of measles during periods of low disease inci-
dence and for documenting the impact of measles elimination efforts (16 ). In addition
to serologic confirmation, a specimen (e.g., urine or nasopharyngeal mucus) for mea-
sles virus isolation and genetic characterization should be collected as close to the
time of rash onset as possible. Delay in collection of these clinical specimens reduces
the chance of isolating measles virus. Clinicians who have a patient with suspected
measles should immediately contact their local or state health departments concern-
ing additional information about collecting and shipping urine and nasal specimens
for measles virus isolation. Molecular characterization of the measles virus isolated
from urine or nasopharyngeal specimens requires considerable time and cannot be
used for diagnosis of measles. Use of oral fluid in tests for detecting measles IgM and
IgG antibodies is being investigated (225 ).
Measles Outbreak Control
The local or state health department should be contacted immediately when sus-
pected cases of measles occur in a community. All reports of suspected measles cases
should be investigated promptly. Because of the potential for rapid spread of the dis-
ease, one confirmed case of measles in a community is an urgent public health
situation. Once a case is confirmed, prompt vaccination of susceptible persons at risk
for exposure may help prevent dissemination of measles. Control activities should not
be delayed pending the return of laboratory results from persons with suspected or
probable cases. Persons who cannot readily provide acceptable evidence of measles
immunity (Table 1) should be vaccinated or excluded from the setting of the outbreak
(e.g., school, day care facility, hospital, clinic). Almost all persons who are excluded
from an outbreak area because they lack acceptable evidence of immunity quickly
comply with vaccination requirements. Persons exempted from measles vaccination
for medical, religious, or other reasons should be excluded from involved institutions
in the outbreak area until 21 days after the onset of rash in the last case of measles.
Mass revaccination of entire communities generally is not necessary. Staff of the
National Immunization Program, CDC, are available to assist health departments in
developing an outbreak control strategy.
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Measles Outbreaks Among Preschool-Aged Children
Although most infants are protected from measles by maternal antibody, the dis-
ease is often more severe when it affects children aged <12 months. If cases are
occurring among infants aged <12 months, measles vaccination of infants aged as
young as 6 months may be undertaken as an outbreak control measure. Monovalent
measles vaccine is preferred, but MMR vaccine may be administered if the monova-
lent vaccine is not readily available (see Routine Vaccination—International Travel).
Children vaccinated with measles or MMR vaccine before the first birthday should be
revaccinated at age 12–15 months and again before entering school.
Passive immunization with IG may be preferred for infants aged <12 months who
are household contacts of measles patients, both because it is likely they will have
been exposed >72 hours before diagnosis of the disease in the household member
and because they are at highest risk for complications from the disease (see Use of
Vaccine and Immune Globulin Among Persons Exposed to Measles, Rubella, or
Mumps). IG should not be used to control measles outbreaks.
Measles Outbreaks in Day Care Facilities, Schools, and Other Educational Institutions
During an outbreak in a day care facility, revaccination with MMR is recom-
mended for all attendees and their siblings who have not received two doses of
measles-containing vaccine on or after the first birthday and who do not have other
evidence of measles immunity. Facility personnel (e.g., employees, volunteers, serv-
ice providers) who cannot provide acceptable evidence of immunity (Table 1) also
should be vaccinated with MMR. Revaccination also should be considered for unaf-
fected child care facilities in the community that may be at risk for measles exposure
and transmission. 
During outbreaks in schools (elementary, middle, junior and senior high schools,
colleges and other institutions of higher education), a program of revaccination with
MMR vaccine is recommended in the involved schools. Revaccination of students and
personnel of unaffected schools in the same geographic area who may be at risk for
measles transmission also should be considered. Revaccination should include all stu-
dents and their siblings and all school personnel born during or after 1957 who cannot
provide documentation of adequate measles vaccination or other acceptable evidence
of measles immunity. For persons born in 1957 or later, adequate vaccination consists
of two doses of measles-containing vaccine separated by at least 28 days with the first
dose administered no earlier than the first birthday (Table 1) ( see Documentation of
Immunity). Persons who cannot readily provide documentation of acceptable evi-
dence of measles immunity should be vaccinated or excluded from the day care
facility, school, or other educational institution. Revaccinated persons, as well as per-
sons who receive their first dose as part of the outbreak control program, may be
readmitted to school immediately. Persons exempted from measles vaccination for
medical, religious, or other reasons, and those who refuse vaccination for any reason,
should be excluded from the day care facility, school, or other educational institution
until 21 days after the onset of rash in the last case of measles.
Measles Outbreaks in Health-Care Settings
If a measles outbreak occurs within a health-care facility (e.g., hospital, clinic, phy-
sician office) or in the areas served by the facility, all persons working at the facility
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who cannot provide documentation of two doses of measles-containing vaccine sepa-
rated by at least 28 days with the first dose administered on or after the first birthday,
or who do not have other evidence of measles immunity (Table 1), should receive a
dose of MMR vaccine. If indicated, health-care workers born during or after 1957
should receive a second dose of MMR vaccine at least 28 days after the previous dose
(see Documentation of Immunity). Some health-care workers born before 1957 have
acquired measles in health-care facilities and have transmitted the disease to patients
or coworkers (see Health-care Facilities). Therefore, during outbreaks, health-care fa-
cilities also should strongly consider recommending a dose of MMR vaccine to
unvaccinated health-care workers born before 1957 who do not have serologic evi-
dence of immunity or a history of measles disease.
Serologic testing of health-care workers before vaccination is not generally recom-
mended during an outbreak because arresting measles transmission requires rapid
vaccination of susceptible health-care workers. The need to screen, wait for results,
and then contact and vaccinate susceptible persons can impede the rapid vaccination
needed to curb the outbreak.
Susceptible health-care workers (Table 1) exposed to measles should receive a
dose of MMR vaccine and should be removed from all patient contact and excluded
from the facility from the fifth to the 21st day after the exposure. They may return to
work on the 22nd day after exposure. However, susceptible health-care workers who
are not vaccinated after exposure should be removed from all patient contact and
excluded from the facility from the fifth day after their first exposure to the 21st day
after the last exposure, even if they receive postexposure IG. Personnel who become
ill with prodromal symptoms or rash should be removed from all patient contact and
excluded immediately from the facility until 4 days after the onset of their rash.
Use of Quarantine
Imposing quarantine measures for outbreak control is usually both difficult and dis-
ruptive to schools and other organizations. Under special circumstances (i.e., during
outbreaks in schools attended by large numbers of persons who refuse vaccination),
restriction of an event or other quarantine measures might be warranted (226). How-
ever, such action is not recommended as a routine measure for control of most
outbreaks.
Rubella Case Investigation and Outbreak Control
Case Definition
A suspected rubella case is any generalized rash illness of acute onset. A clinical
case of rubella is defined as an illness characterized by all of the following clinical
features: 
• acute onset of generalized maculopapular rash; and
• a temperature of >37.2 C (>99 F), if measured; and
• arthralgia/arthritis, or lymphadenopathy, or conjunctivitis. 
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Cases meeting the measles case definition are excluded, as are cases with serologic
findings compatible with recent measles virus infection. 
A probable case of rubella 
• meets the clinical case definition for rubella, and
• has no or noncontributory serologic or virologic testing, and
• is not epidemiologically linked to a laboratory-confirmed case. 
A confirmed rubella case
• meets the laboratory criteria for rubella, or
•  meets the clinical case definition and is epidemiologically linked to a laboratory
confirmed case.
Suspected and known rubella cases should be reported immediately to local health
departments. Aggressive case finding and intensified surveillance for CRS should fol-
low. Rubella surveillance is complicated by the nonspecific nature of the symptoms of
the clinical disease. Rubella can be confused with other illnesses, including measles.
Thus, all rubella cases, particularly isolated cases that do not occur as part of an out-
break, should be confirmed by laboratory testing. Confirmed rubella cases are
reported to the CDC by state health departments. Cases of febrile rash illness that are
laboratory-negative for rubella may be measles (rubeola) and the patients should be
tested for measles IgM.
Laboratory confirmation of suspected cases of CRS also is necessary because the
constellation of findings of CRS varies. Case reports of indigenous congenital rubella
syndrome are sentinel events, indicating the presence of rubella infections in the com-
munity that may previously have been unrecognized. The diagnosis of one or more
indigenous CRS cases in a community should trigger intensified rubella and CRS sur-
veillance.
A confirmed case of CRS has laboratory confirmation of rubella infection and
at least one defect in each of the two following categories: a) cataracts/congenital
glaucoma (either or both count as one), congenital heart disease, loss of hearing, pig-
mentary retinopathy; and, b) purpura, splenomegaly, jaundice, microcephaly, mental
retardation, meningoencephalitis, radiolucent bone disease. 
A probable case of CRS has any two conditions listed in category a) or one from
category a) and one from category b) and lacks evidence of any other etiology. A case
with laboratory evidence of rubella infection but no clinical symptoms or signs of CRS
is classified “infection only.”
Laboratory Diagnosis
The criteria for laboratory diagnosis of rubella are
• a positive serologic test for rubella IgM antibody; or
• a significant rise between acute- and convalescent-phase titers in serum rubella
IgG antibody level by any standard serologic assay; or
• the isolation of rubella virus from an appropriately collected clinical specimen. 
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The clinical diagnosis of acute rubella should be confirmed by laboratory testing
(230 ). The demonstration of rubella-specific IgM antibody is the most commonly used
method to obtain serologic confirmation of acute rubella infection. Rubella-specific
IgM antibody usually becomes detectable shortly after rash onset. The IgM antibody
peaks approximately 7 days after rash onset and remains detectable for 4–12 weeks,
although it is more likely to be detectable if the serum specimen is obtained within
4–5 weeks after rash onset. Occasionally, rubella-specific IgM antibody can be de-
tected up to 1 year after acute infection.
To test for IgM, one serum specimen can be obtained as early as 1–2 days after rash
onset. If IgM is not detectable in this first specimen, a second serum specimen should
be collected 5 days after the onset of rash or as soon as possible thereafter. False-
negative rubella IgM antibody test results may sometimes occur even if the specimen
is appropriately drawn. False-positive IgM test results may occur among persons with
certain viral infections (e.g., acute infectious mononucleosis, cytomegalovirus, or par-
vovirus) and among persons who are rheumatoid factor positive. 
For IgG assays, the criteria for a significant rise in rubella antibody level vary
by type of assay and by laboratory. For HI assays, a fourfold rise in the titer of antibody
indicates recent infection. The acute-phase serum specimen should be obtained
as soon after rash onset as possible, preferably within 7 days. The convalescent-
phase serum specimen should be drawn at least 10 days after the acute-phase serum
specimen. The acute- and convalescent-phase serum specimens should be tested si-
multaneously in the same laboratory. If the acute-phase serum specimen is drawn
>7 days (and occasionally even if obtained within 7 days) after rash onset, a significant
rise in antibody titer may not be detected by most commonly used IgG assays.
In the absence of rash illness, the diagnosis of subclinical cases of rubella can be
facilitated by obtaining the acute-phase serum specimen as soon as possible after
exposure. The convalescent-phase specimen should be drawn at least 28 days after
exposure. If acute- and convalescent-phase paired sera provide inconclusive results,
rubella-specific IgM antibody testing can be performed. Expert consultation may be
necessary to interpret the data.
Among pregnant women of unknown immune status who experience a rash illness
or who are exposed to rubella, laboratory confirmation of rubella infection may be
difficult. A serum specimen should be obtained as soon as possible. Unfortunately,
serologic results are often nonconfirmatory. Such situations can be avoided by per-
forming routine prenatal serologic screening of women who do not have acceptable
evidence of rubella immunity (see Documentation of Immunity and Women of Child-
bearing Age). In addition, health-care providers should request that laboratories
performing prenatal serologic screening retain such specimens until delivery, in case
retesting is necessary.
Congenital Rubella
Suspected cases of CRS should be managed with contact isolation (228 ). While
diagnostic confirmation is pending, children with suspected CRS should be cared for
only by personnel known to be immune to rubella. Confirmation of diagnosis by virus
isolation can be done by culturing nasopharyngeal and urine specimens. Serologic
confirmation can be obtained by testing cord blood for the presence of rubella-specific
IgM antibodies. An alternative method for infants aged ≥3 months is to document
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rubella-specific antibody levels that do not decline at the rate expected from passive
transfer of maternal antibody (i.e., the equivalent of a twofold decline in HI titer per
month). However, some infected infants may have low antibody levels because of
agammaglobulinemia or dysgammaglobulinemia.
In some infants with CRS, rubella virus can persist and can be isolated from naso-
pharyngeal and urine cultures throughout the first year of life or longer (229 ).
Children with CRS should be presumed infectious at least through the first year of life
unless nasopharyngeal and urine cultures are negative for virus after age 3 months
(230 ). Some authorities suggest that an infant who has CRS should be considered
infectious until two cultures of clinical specimens obtained 1 month apart are negative
for rubella virus (230 ). Precautions should be taken to ensure that infants with CRS do
not cause additional rubella outbreaks. Specifically, all persons who have contact with
a child with CRS (e.g., care givers, household contacts, medical personnel, laboratory
workers) should be immune to rubella (Table 1) (see Documentation of Immunity and
Routine Vaccination).
Rubella Outbreak Control
Outbreak control is important for eliminating CRS. Aggressive responses to out-
breaks may interrupt chains of transmission and can increase vaccination coverage
among persons who might not be protected otherwise. Although methods for control-
ling rubella outbreaks are evolving, the main strategy should be to define target
populations for rubella vaccination, ensure that susceptible persons within the target
populations are vaccinated rapidly (or excluded from exposure if a contraindication to
vaccination exists), and maintain active surveillance to permit modification of control
measures as needed.
Control measures should be implemented as soon as a case of rubella is confirmed
in a community. This approach is especially important in any outbreak setting involv-
ing pregnant women (e.g., obstetric-gynecologic and prenatal clinics). All persons at
risk who cannot readily provide laboratory evidence of immunity or a documented
history of vaccination on or after the first birthday should be considered susceptible
and should be vaccinated unless vaccination is contraindicated (Table 1) (see Docu-
mentation of Immunity).
Rubella Outbreaks in Schools or Other Educational Institutions
An effective means of terminating rubella outbreaks and increasing rates of
vaccination quickly is to exclude from possible contact persons who cannot pro-
vide valid evidence of immunity. Experience with measles outbreak control
indicates that almost all students who are excluded from school because they
lack evidence of immunity quickly comply with vaccination requirements and are
promptly readmitted to school. Persons exempted from rubella vaccination for
medical, religious, or other reasons should also be excluded from attendance.
Exclusion should continue for 3 weeks after the onset of rash of the last reported
case in the outbreak setting. Less rigorous approaches (e.g., voluntary appeals
for vaccination) have not been effective in terminating outbreaks.
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Rubella Outbreaks in Health-Care Settings
During rubella outbreaks in health-care settings where pregnant women may be
exposed, mandatory exclusion and vaccination of health-care workers who lack evi-
dence of rubella immunity (Table 1) should be practiced. Exposed health-care workers
who lack evidence of immunity should be excluded from duty from the seventh day
after first exposure through the twenty-first day after their last exposure or until 5 days
after the rash appears. In addition, because birth before 1957 does not guarantee ru-
bella immunity, health-care facilities should strongly consider recommending a dose
of MMR vaccine to unvaccinated health-care workers born before 1957 who do not
have serologic evidence of immunity. Although rubella vaccination during an out-
break has not been associated with substantial personnel absenteeism (116,191 ),
vaccination of susceptible persons before an outbreak occurs is preferable because
vaccination causes far less absenteeism and disruption of routine work activities than
does rubella infection.
Mumps Case Investigation and Outbreak Control
Case Definition
A clinical case of mumps is defined as an illness characterized by acute onset of
unilateral or bilateral tender, self-limited swelling of the parotid or other salivary gland
lasting ≥2 days, and without other apparent cause (as reported by a health profes-
sional). 
A probable case of mumps
• meets the clinical case definition of mumps, and
• is not epidemiologically linked to a confirmed or probable case, and
• has noncontributory or no serologic or virologic testing. 
A confirmed case of mumps 
• meets the laboratory criteria for mumps, or 
• meets the clinical case definition and is epidemiologically linked to a confirmed
or probable case. 
A laboratory-confirmed case need not meet the clinical case definition. Two prob-
able cases that are epidemiologically linked are considered confirmed, even in the
absence of laboratory confirmation.
Reporting of mumps often has been based solely on clinical diagnosis without
laboratory confirmation. However, parotitis may have other infectious and noninfec-
tious causes. Therefore, serologic confirmation of the diagnosis is preferred. Use of
criteria for clinical diagnosis that are both stricter and more reliable, combined with
laboratory confirmation, can be expected to decrease the number of false positive
mumps cases reported and allow a more accurate assessment of mumps incidence. 
Probable or confirmed cases of mumps should be reported immediately to state
and local health departments. Recommended procedures to enhance the comprehen-
siveness of reporting include identification of all contacts, follow-up of susceptible
contacts, and serologic testing of all probable cases to confirm the diagnosis.
46 MMWR May 22, 1998
Laboratory Diagnosis
The laboratory criteria for the diagnosis of mumps are
• isolation of the mumps virus from a clinical specimen, or
• a significant rise between acute and convalescent-phase titers in serum mumps
IgG antibody level by any standard serologic assay, or
• a positive serologic test for mumps IgM antibody.
In a prospective study in the practices of family practitioners in a Canadian commu-
nity, one-third of persons with clinically diagnosed cases of mumps had no serologic
evidence of recent mumps infection (28 ). Serum mumps IgM IFA tests are commer-
cially available. However, until more data are available concerning the use and
interpretation of these tests, laboratory confirmation of mumps should be based on
tests of demonstrated reliability. State health department laboratories can provide
guidance when testing for acute mumps infection is necessary. 
Mumps Outbreak Control
The strategy for outbreak control includes three main elements. The target popula-
tion (transmission setting) must be defined. Persons within the population who are
susceptible to mumps must be identified and vaccinated. Consideration should be
given to excluding susceptible persons who are exempt from vaccination (for medical,
religious, or other reasons) from the affected institution or setting until the outbreak is
terminated. Active surveillance for mumps should be conducted until two incubation
periods (i.e., 5–6 weeks) have elapsed since onset of the last case.
School-based Mumps Outbreaks
Exclusion of susceptible students from schools affected by a mumps outbreak (and
other, unaffected schools judged by local public health authorities to be at risk for
transmission of the disease) should be considered among the means to control
mumps outbreaks. Excluded students can be readmitted immediately after they are
vaccinated. Experience with outbreak control for other vaccine-preventable diseases
indicates that almost all students who are excluded from the outbreak area because
they lack evidence of immunity quickly comply with requirements and can be readmit-
ted to school. Pupils who have been exempted from mumps vaccination for medical,
religious, or other reasons should be excluded until at least 26 days after the onset of
parotitis in the last person with mumps in the affected school.
Mumps Outbreaks in Health-Care Settings
Sporadic nosocomial cases of mumps have occurred in long-term care facilities
housing adolescents and young adults (122 ). However, mumps virus is less transmis-
sible than measles and other respiratory viruses. The low level of mumps trans-
mission in the community results in a low risk for introduction of the disease into
health-care facilities. Because mumps is shed by infected persons before clinical
symptoms become evident and because infected persons often remain asympto-
matic, an effective routine MMR vaccination program for health-care workers is the
best approach to prevent nosocomial transmission.
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To prevent droplet transmission of the disease, respiratory isolation precautions for
persons with mumps should be maintained for 9 days after onset of symptoms (e.g.,
parotitis). If exposed to mumps, health-care workers who lack acceptable evidence of
immunity (Table 1) should be excluded from the health-care facility from the 12th day
after the first exposure through the 26th day after the last exposure. Workers in whom
the disease develops should be excluded from work until 9 days after the onset of
symptoms.
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